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1. Introduction 
 
During the last ten years a considerable amount of knowledge has been accumulated 
on the function of trefoil peptides. Indeed, they not only play an important role in the 
protecting and healing processes of the stomach and intestine, but also demonstrate 
how crucial these small proteins are for the normal functioning of the gastrointestinal 
(GI) tract. Trefoil peptides are a small family of polypeptides, secreted predominantly by 
mucous cells in the gut. This family is composed of 3 mammalian members: TFF1 (or 
pS2), a gastric peptide; TFF2 or (spasmolytic polypeptide, SP), a distal gastric peptide; 
and TFF3 (or intestinal trefoil factor, ITF), which is found mainly in the intestine and 
colon. Two gene knockout studies in particular (Lefebvre et al., 1996; Mashimo et al., 
1996) have demonstrated that normal trefoil peptide expression is vital to the dynamic 
processes of epithelial restitution and surface protection. 
 
The mouse is one of the most widely used laboratory animals for studying mammalian 
biochemistry and developmental biology. Its popularity is largely due to an impressive 
range of transgenic and genetic techniques which allow researchers to manipulate or 
even "knockout" mouse gene expression. 
In connection with the exponential increase in the number of genes identified by various 
genome projects, e.g. HUGO (Lander et al., 2001; Venter et al., 2001), it has become 
imperative to use efficient methods respectively for determining gene function in vivo in 
a mammalian organism. 
Transgenic mice are produced by the injection of one or more transgenes into the 
pronucleus of a fertilised mouse oocyte, which results in the birth of a transgenic mouse 
carrying one to several copies of the transgene. 
The use of gene knockout (selective removal of a gene by homologous recombination) 
has become a extremely effective approach that allows scientists to study and 
understand what individual genes may do. Two major elements are needed to produce 
a mutant mouse strain by homologous recombination: (1) an embryonic stem (ES) cell 
line (Mansour et al., 1988; Ramirez-Solis et al., 1993; Zimmer, 1992) capable of 
contributing to the germline and (2) a targeting construct containing target-gene 
sequences with the desired mutation. Once identified, mutant ES cell clones can be 
injected into a blastocyst in order to produce a chimeric mouse. The breeding of germ-
line chimeras yields animals that are heterozygous for the mutation. These can be 
interbred to produce homozygous mutant “knockout” mice. 
  Introduction 
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1.1  Trefoil peptides 
 
Trefoil factors (TFFs) constitute a family of mucin-associated peptides containing one or 
more structurally characteristic trefoil domains (Thim, 1989). 
 
The trefoil domain 
Trefoil peptides share similarity in cysteine-rich regions of 38 or 39 amino acids known 
as trefoil domains/motifs (also termed P-domains) in which cysteine residue-disulphide 
bonds are formed according to an invariable 1-5, 2-4, 3-6 design. This amino acid 
sequence, together with the disulphide bonds, form a characteristic three-leaved (clover 
leaf) structure which has given the peptide family its name (Fig. 1). The minimum 
requirement for a trefoil domain would be the presence of the consensus sequence 
(CX9-10CGX8CX4CCX9WCF)(Hoffmann and Hauser, 1993; Thim, 1989; Thim, 1997). 
 
The suggested disulphide arrangement was later confirmed by several three-
dimensional structure determinations of trefoil domains (Carr, 1992; Carr et al., 1994; 
Gajhede et al., 1993). 
Since this structural motif is extremely stable, these peptides have an extraordinary 
resistance to acid hydrolysis and proteolysis, and thus, making them well suited for 
activity in the harsh, luminal environment of the gut. 
 
Members of this family have been discovered in various species. In mammals (e.g., 
man, mouse, and rat) three paralogous members designated as TFF1, TFF2, and TFF3 
have been identified. In addition, in Xenopus, an African clawed frog, TFF-related 
proteins containing either one, two, four or six copies of the TFF domain have been 
documented. Table 1 summarises the collected data on the number of trefoil domains 
and main sites of expression. Interestingly enough, all TFFs and TFF-related proteins 
are normally expressed in mucin secreting tissues, namely the GI tract mucosa and the 
skin of Xenopus laevis. 
 
When taken together, these data demonstrate that the trefoil domain, which has been 
well-preserved throughout evolution from amphibia to mammals, is likely to display 
important conserved functions (Sommer et al., 1999). 
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Nomenclature 
As a result of a nomenclature discussion on trefoil (P-domain) peptides at a Philippe 
Laudat Conference (autumn 1996, Aix-les-Bains, France), the scientific organising 
committee of the meeting recommended the use of a TFF (TreFoil Factor) 
nomenclature system for mammalian peptides, i.e. TFF1 for pS2/BCEI, TFF2 for SP 
and TFF3 for ITF/P1.B (P-domain 1.B)(Wright et al., 1997). 
It was further recommended that different species be marked by a lowercase letter 
prefixed to the peptide name, e.g. hTFF3 for human, mTFF2 for mouse rTFF1 for rat 
etc.. Moreover genes encoding the trefoil peptides were to be written in italics (TFF1,...) 
and the corresponding peptides in non-italic letters (TFF1,...). In addition, the standard 
“Genetic Nomenclature for Mice” was to be used. Mouse locus symbols, then, begin 
with a capital letter followed by lower-case letters (Tff1, Tff2, Tff3). 
 
 
Table 1: Number of trefoil domains and major sites of expression of trefoil peptides grouped according to 
their homology (FIM: Frog integumentary mucin, X: Xenopus) 
 
Name Trefoil 
domains 
Major sites References 
    
human TFF1 1 Stomach Masiakowski et al. 1982, Rio et al. 1988 
mouse TFF1 1 Stomach Lefebvre et al. 1993, Otto et al. 1996,  
rat TFF1 1 Stomach Itoh et al. 1996 
X. laevis xP1 1 Stomach Hauser and Hoffmann, 1991 
    
human TFF2 2 Stomach Tomasetto et al. 1990 
mouse TFF2 2 Stomach Tomasetto et al. 1990, Lefebvre et al. 1993 
rat TFF2 2 Stomach Jeffrey et al. 1994 
porcine TFF2  2 Pancreas Jørgensen et al. 1982, Tomasetto et al. 1990
    
human TFF3 1 Intestine Hauser et al. 1993, Podolsky et al. 1993 
mouse TFF3 1 Intestine Mashimo et al. 1995 
rat TFF3 1 Intestine Suemori et al. 1991, Chinery et al. 1992 
    
X. laevis xP2 2 Skin Hauser et al. 1992 
X. laevis xP4 4 Stomach Hauser and Hoffmann, 1991 
X. laevis FIM-A.1a 4 Skin Hoffmann 1988, Hauser et al. 1990 
X. laevis FIM-C.1a 6 Skin Hauser and Hoffmann, 1992 
a larger proteins containing also mucin–like sequences 
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1.2  Members of the trefoil peptide family  
 
1.2.1  Trefoil peptides in mammals 
 
TFF1 
Human TFF1 was discovered in 1982 while screening for oestrogen-inducible mRNAs 
in the library of the breast carcinoma cell line MCF-7. Masiakowski et al. (Masiakowski 
et al., 1982) cloned this oestrogen-inducible cDNA designated pS2. The human 
pS2/TFF1 gene codes for a small pre-protein of 84 amino acids contains an 
aminoterminal signal peptide characteristic of secreted proteins (Jakowlew et al., 1984; 
May and Westley, 1988). The secreted mature form of TFF1 is a 6,6 kDa protein of 60 
amino acids (Fig. 1A)(Mori et al., 1990) and displays an N-terminal pyro-glutamic acid 
residue (Rio et al., 1988), a trefoil domain, and a carboxy-terminal acidic domain. The 
nucleotide sequence of the oestrogen-induced element, formerly called pS2, was 
published two years later (Jakowlew et al., 1984; Prud'homme et al., 1985). 
Although TFF1 is derived from a breast cancer cell line and expressed in about 60% of 
human breast carcinomas (which can be sometimes of prognostic value)(Rio and 
Chambon, 1990), it is not a major constituent of normal breast tissue. In contrast to the 
insignificant amounts of mRNA and protein detectable in the normal breast, TFF1 is 
usually represented with high levels in the human stomach (Rio et al., 1988). 
 
The discovery of TFF1 homologues in mice, with proteins of either 62 or 66 amino acids 
(Lefebvre et al., 1993; Otto et al., 1996) and in rats (Itoh et al., 1996; Table 1) has 
confirmed that these mammalian peptides are conserved during evolution (Sands and 
Podolsky, 1996). 
 
Certain evidence suggests that TFF1 can exist as a dimer, bridging over the seventh 
cysteine residue (Cys58) to another TFF1 molecule. Though this ability might be 
functionally important, it further illustrates the possible role of specific residues in 
binding (Chadwick et al., 1997; Polshakov et al., 1997). Western transfer analysis has 
shown, that TFF1 is present in different molecular forms intimately associated with 
mucus in normal stomach (Newton et al., 2000). Tomasetto et al. also demonstrated 
that mouse TFF1 interacts directly with the VWFC (von Willebrand factor C) cysteine-
rich domains of mucins (Tomasetto et al., 2000). 
 
  Introduction 
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        A 
 
 B 
 
 
Figure 1: Amino acid sequence and proposed secondary structure of human trefoil peptides pS2/TFF1 
(in comparison to a clover leaf) (A), SP/TFF2, and ITF/TFF3 (B) with the disulphide bonding of cysteine 
residues 1-5, 2-4, 3-6. Adapted after Plaut (1997) and Thim (1997). 
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TFF2 
TFF2 was identified in 1990 (Tomasetto et al., 1990) as a human homologue of a 
peptide isolated from the porcine pancreas, and originally called pancreatic spasmolytic 
polypeptide (pSP). The pSP was first isolated by Jørgensen et al. (Jørgensen et al., 
1982a) in 1982 within a side-fraction obtained by purifying insulin from a porcine 
pancreas. It was found to be abundant in porcine pancreas (100 mg/kg)(Thim et al., 
1982), in contrast to pS2/TFF1, where enough peptide was available to perform various 
physiological and pharmacological studies. 
The human variant was named spasmolytic polypeptide (SP), since the pancreas did 
not seem to be a major site of expression. Several years later it was discovered that 
these peptides (pS2 and pSP) share a common unique sequence motif (Baker, 1988; 
Thim, 1988) later named the trefoil domain (Thim et al., 1989). 
 
The mature hTFF2 is a 12 kDa protein composed of 106 amino acids and contains two 
trefoil domains separated by a short sequence of amino acid residues (Fig. 1B left). The 
structure of pSP has been studied in detail by 3-D structure analysis (Carr et al., 1994; 
De et al., 1994), and regions have been identified on the surface which are candidates 
for interacting with oligosaccharide chains or putative receptors. The TFF2 protein was 
recently found to be glycosylated via an N-linkage (May et al., 2000) but little is known 
concerning the possible function of this glycosylation. 
Homologous peptides to pSP have been identified in other species such as rat and 
mouse (Table 1). A considerable conservation of amino acid residues is evident among 
TFF2 from different mammalian species (Poulsom, 1996). The first trefoil motif (the 
most N-terminal) is more strongly related to the single-trefoil motifs present in either 
TFF1 or TFF3. The (second) trefoil motif close to the C-terminus perhaps evolved later 
by an incomplete duplication event (Kayademir et al., 2000). 
 
TFF3 
The third mammalian protein in the family, TFF3 (Fig. 1B right; originally known as 
intestinal trefoil factor-ITF- or hP1.B) was later discovered as a rat cDNA sequence from 
a rat jejunal library in 1991 (Suemori et al., 1991), while the human cDNA sequence 
was reported in 1993 (Hauser et al., 1993; Podolsky et al., 1993). Clones for the rat 
were picked using oligonucleotide probes based on the peptide sequence of human 
TGIF (transformed growth-inhibitory factor; Podolsky et al., 1988). Consequently, a 
relationship between TFF3 and TGIF has not been confirmed. 
Sequence analysis has revealed that TFF3 from human, rat, and mouse sources (Table 
1; Mashimo et al., 1995) are single trefoil peptides (like TFF1) of 59 amino acids 
residues. Gel filtration analysis of extracts taken from human and rat tissues revealed 
only a monomeric ~6.6 kDa form (Taupin et al., 1995). A dimerization of TFF3, 
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however, seems to occur naturally (Chinery and Playford, 1995), when expressed in 
bacteria (Chinery et al., 1995) and yeast (Thim et al., 1995). Characterisation of purified 
rTFF3 verified that both monomers and dimers can be observed under reducing and 
non-reducing conditions, respectively. 
Site-directed mutagenesis studies illustrate that Cys57 is necessary for rTFF3 dimer 
formation. Samples of human gastrointestinal tissue following biopsy also demonstrate 
the presence of reducible human TFF1 and TFF3 covalent dimers (Chinery et al., 
1995). Thus, these results raise the intriguing possibility that a spectrum of biological 
activities may be generated by combining different single-trefoil peptides. 
 
 
1.2.2  Amphibian trefoil proteins 
 
A trefoil protein, originally called spasmolysin (Hoffmann, 1988), was first cloned from 
the skin of the clawed frog Xenopus laevis. Initially, this relatively large (~130 kDa) 
protein was presumed to undergo post-translational processing to yield two single 
trefoil-motif containing peptides, as well as another peptide bearing two trefoil motifs, 
and a region of extensive glycosylation (Hoffmann, 1988). Subsequently, this protein, 
called frog integumentary mucin-A.1 (FIM-A.1), was found not to be cleaved. Thus FIM-
A.1 exists in X. laevis skin as a peptide containing four trefoil domains, in addition to 
extensively glycosylated domains containing mucin-type, O-glycosidally-linked oligo-
saccharide side chains (Hauser et al., 1990). 
Other trefoil-motif containing proteins secreted onto the frog’s skin include a second 
FIM, which contains six trefoil domains (FIM-C.1; Hauser and Hoffmann, 1992) and a 
double trefoil domain protein, called APEG protein (Gmach et al., 1990). In contrast, 
xP2, a protein with two trefoil domains, though present in skin, does not appear to be 
secreted onto mucus coating of the skin (Hauser et al., 1992). 
With respect to the identification of family members within the amphibian stomach, two 
proteins were found and designated xP1 (homologue of the TFF1 gene product) and 
xP4, containing one and four trefoil motifs. Both of these proteins are expressed by 
surface mucous cells of X. laevis’ gastric mucosa (Hauser and Hoffmann, 1991). 
Because of the quasi-tetraploid genome (Thiebaud and Fischberg, 1977) of X. laevis, 
two xP4 genes were found, xP4.1 and xP4.2, differentially expressed (Botzler et al., 
1999). 
The evolutionary conservation of the trefoil motif from amphibian to human proves the 
functional importance of this structure. 
  Introduction 
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1.3  Genomic structure of the human TFF genes 
 
The three human TFF genes are clustered within 50 kb in the chromosomal region 
21q22.3 (Fig. 2)(Chinery et al., 1996a; Gött et al., 1996; Hattori et al., 2000; Schmitt et 
al., 1996; Theisinger et al., 1992; Tomasetto et al., 1992). This gene cluster is 
positioned within a CpG-rich region and is tandemly oriented (tel-TFF1-TFF2-TFF3-cen) 
with a transcription of all three genes directed towards the centromere (Gött et al., 1996; 
Seib et al., 1997). 
Analysis of the exon structure of the three trefoil peptide genes revealed an extremely 
similar organisation. The first exon encodes the secretion signal sequence; the second 
(and the third exon of TFF2) encodes the trefoil domain(s); and the third exon (the 
fourth of TFF2) encodes four to five residues of the carboxyl terminus. This conserved 
structural organisation may have evolved from gene duplication and exon shuffling (Gött 
et al., 1996). 
 
 
 
 
 
 
 
Figure 2: The region on chromosome 21q22.3 and the genomic organisation of the gene cluster that 
encodes the human trefoil peptides. Coloured boxes represent the trefoil genes (TFF1,...). 
 
 
The TFF1 gene, formerly known as BCEI (breast cancer oestrogen inducible) gene, is 
formed by three exons (Rio and Chambon, 1990), with the single trefoil domain 
encoded by exon 2. The promoter region of TFF1 contains several control elements, all 
located within 1 kb: an oestrogen responsive element (ERE) as well as elements 
responsive to phorbol esters, epidermal growth factors, c-Ha-ras, and c-jun (Berry et al., 
1989; Cavailles et al., 1989; Nunez et al., 1989). 
The structure of the TFF2 gene, whose locus was designated SML1 (spasmolysin 1) 
contains four exons and is the only gene encoding two trefoil domains by exons 2 and 3 
(Tomasetto et al., 1990). These exons are separated by an intron containing an unique 
25 bp tandem repeat cluster, repeated approximately 48 to 53 times (Kayademir et al., 
1998). 
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Analysis of the TFF3 gene reveals the same basic structure of three exons as TFF1 
(Hauser et al., 1993; Podolsky et al., 1993; Seib et al., 1995).  
 
Besides gene clustering and transcriptional orientation, all three genes display a 
collection of regulatory signal sequences in their 5'-region sharing several motifs (e.g., 
the HNF-3 binding site; Beck et al., 1999) with almost identical sequences or high 
sequence homology and spacing, suggesting a coordinated regulation and/or a 
common locus-controlling region (Gött et al., 1996). 
Two motifs with identical sequence and position are shared exclusively by the stomach-
specific genes TFF1 and TFF2, thus, presenting possible targets for stomach specific 
gene regulation. In addition, the genes react in a comparable fashion to stimuli such as 
osmolarity changes (Ludeking et al., 1998) or show (only TFF1) a unique activation 
response to steroid hormones (Beck et al., 1997). 
 
 
1.4  Expression of trefoil peptides 
 
1.4.1  Expression in normal human tissues 
 
The predominant site of expression of all three mammalian (and human) TFF is in the 
gastrointestinal (GI) epithelial cells (Table 2). 
Under normal circumstances TFF1 and TFF2 are mainly expressed in the stomach (Rio 
et al., 1988; Tomasetto et al., 1990), and TFF3 in the small and large intestine (Suemori 
et al., 1991)(Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Restricted expression of TFFs along the GI tract. 
TFF1 is expressed in the stomach (red/yellow stripes), TFF2 
in stomach and duodenum (yellow/blue stripes), and TFF3 in 
the small and large intestine (blue). Adapted after Ribieras 
et al. (1998). 
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Table 2 summarises data (incomplete) concerning sites of physiological expression of 
trefoil factors in normal human tissues. 
 
 
Table 2: Sites of expression of TFF domain peptides in normal human tissues 
 
Trefoil peptide Organ / Site Description References 
TFF1 Stomach Mucus cells from neck upwards, all 
regions 
Rio et al., 1988; Luqmani et 
al., 1989; Hanby et al., 1993 
 Small Intestine Ductal luminal cells of Brunner’s 
glands 
Hanby et al., 1993 
 Large Intestine Goblet cells near surface of crypts Singh et al., 1998 
 Pancreas Focally in duct epithelium Wright et al., 1990 
 Salivary glands Patchy epithelial expression Rio et al., 1988; Devine et al., 
2000 
 Breast Focally in duct luminal cells Poulsom et al., 1997 
 Eye Conjunctival goblet cells Langer et al., 1999 
 Lung 
respiratory tract 
Focally in epithelial (goblet and 
ciliated) cells of trachea and bronchi 
dos Santos Silva et al., 2000 
TFF2 Stomach Fundus; mucous neck cells of 
antrum; mucous cells in base of 
glands 
Hanby et al., 1993 
 Small intestine Brunner’s glands (acini and distal 
ducts) 
Piggott et al., 1991 
 Pancreas Focally in duct epithelium Wright et al., 1990 
 Gall bladder Patchy epithelial expression Seitz et al., 1991 
TFF3 Small intestine Brunner’s glands (acini and ducts, 
goblet cells) 
Suemori et al., 1991; Chinery 
et al., 1992; Hauser et al., 
1993 
 Large intestine Superficial goblet cells Suemori et al., 1991; Chinery 
et al., 1992; Hauser et al., 
1993 
 Uterus Epithelium Hauser et al., 1993 
 Breast Focally in duct luminal cells Poulsom et al., 1997 
 Brain Hypothalamus, Pituitary Probst et al., 1996 
 Salivary glands Abundantly in most mucous cells Devine et al., 2000 
 Lung 
respiratory tract 
Mucous cells in the acini of sub-
mucosal glands, goblet cells of 
bronchi 
Wiede et al., 1999; dos 
Santos Silva et al., 2000 
 Eye Conjunctival goblet cells Langer et al., 1999 
 
 
TFF1 is abundantly expressed in the mucosa cells of the superficial and foveolar 
epithelium (Rio et al. 1988; Luqmani et al., 1989; Hanby et al., 1993). A high level of 
TFF1 has also been described in upper duct and surface cells of Brunner glands in the 
duodenum (Hanby et al., 1993a). In the pancreas, only a few cells in large ducts appear 
positive (Wright et al., 1990a), which might be due to a response to damage as seen in 
the gall bladder (Seitz et al., 1991). 
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Salivary glands were reported as weakly immunopositive by in situ hybridisation and 
RT-PCR (Rio et al., 1988; Devine et al., 2000). The small intestine generally appears 
not to express TFF1 (though staining of the tips of villi in the ileum and jejunum is 
reported; Piggott et al., 1991). In the large intestine, expression has been demonstrated 
in some goblet cells, particularly in the distal regions (Singh et al., 1998). Outside of the 
GI tract, in other mucous epithelia, TFF1 has been observed focally in duct luminal cells 
of normal breast (Poulsom et al., 1997) and focally in the epithelial (goblet and ciliated) 
cells of trachea and bronchi (dos Santos et al., 2000). Another location of TFF1 is in the 
conjunctiva, where the goblet cells secrete this peptide together with the mucin 
MUC5AC as a constituent of the ocular mucus (Langer et al., 1999). 
 
The expression of TFF2 appears to be highly correlated with that of TFF1 in terms of 
organ specificity. However, although they are co-expressed in stomach cells (Tomasetto 
et al. 1990), TFF1 and TFF2 show striking differences in their cellular localisation, since 
TFF2 is observed in mucous neck cells of the fundus and basal cells of the antral and 
pyloric glands of human stomach (Hanby et al., 1993b). In addition, TFF2 is expressed 
within Brunner’s glands that are confined to the proximal duodenum (Piggott et al., 
1991). Focal expression is also observed in the duct epithelium of pancreas (Wright et 
al., 1990a) and in gall bladder epithelium (Seitz et al., 1991). The principal sites of TFF2 
are indicated in Table 2 and in situ hybridisation data which usually are in agreement 
with the distribution of the peptide. Some exceptions are noted for TFF2; in the gastric 
mucosa. There is also TFF2 mRNA in the gland bases and in the foveolar surface. The 
peptide, however, is undetectable in the surface cells (Hanby et al., 1993b). 
 
While TFF1 and TFF2 are mainly expressed in the stomach, TFF3 is predominantly 
expressed in goblet cells throughout the intestine, in the acini of glands, and distal ducts 
of Brunner’s glands (Suemori et al., 1991; Podolsky et al., 1993; Hauser et al., 1993). 
TFF3 expression has been also observed in human uterus (Hauser et al., 1993), normal 
breast (Poulsom et al., 1997), in salivary glands (Devine et al., 2000), in human 
hypothalamus and pituitary (Probst et al., 1996), and the mucous cells in the acini of 
submucosal glands and goblet cells of bronchi of the lung (dos Santos et al., 2000; 
Wiede et al., 1999). It is also a secretory product of conjunctival goblet cells beside 
TFF1. Together with MUC5AC, they may contribute to the rheological properties of the 
tear film (Langer et al., 1999). 
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1.4.2  Expression in other mammals 
 
Despite the general conservation of expression patterns of different trefoil peptides, 
some variation in the sites of expression among species have been observed. 
 
Pigs 
When pSP (pTFF2) was first isolated from pancreas, this organ was thought to be major 
site for trefoil peptide expression (Thim et al., 1992). Later studies have shown that the 
pig is unique with respect to TFF2. Indeed, the expression of pTFF2 has been localised 
in acinar cells of the pancreas, mucous cells of the stomach and duodenum, and 
epithelial cells in the jejunum and the ileum (Rasmussen et al., 1992). 
 
Rats 
TFF2 expression in rats was found mainly in the antrum (Jeffrey et al., 1994). By 
Northern blot analysis, TFF1 was found expressed abundantly in the stomach and only 
faintly in the duodenum (Itoh et al., 1996). TFF3 was detected in the duodenum and in 
goblet cells of the small intestine and colon (Chinery et al., 1992; Taupin et al., 1995). In 
contrast to this apparent gastrointestinal specificity, TFF3 has been observed in some 
regions of the hypothalamus and in the pituitary gland (Probst et al., 1995; Schwarzberg 
et al., 1999). 
 
Mice 
In mice, TFF1 as well as TFF2 expression have been found in the stomach. A 
comparison of TFF1 and TFF2 gene pattern expression using Northern blots and in situ 
analysis revealed that the peptides were specifically expressed in different tissues 
and/or at different cellular levels in the mouse GI tract, thus, resulting in a 
complementary pattern of expression. 
TFF1 mRNA was shown to be expressed in gastric mucous cells lining the surface 
epithelium and the pits of fundus, antrum, and antrum-pyloric regions. In contrast, TFF2 
was traced in cells, presumably mucous neck cells, confined to the junction between the 
pits and the base of glands within the fundic mucosa, in the base of the antrum, and 
antrum-pyloric glands (Tomasetto et al., 1990; Lefebvre et al., 1993). In the case of 
TFF2, gene expression was also found within the Brunner gland’s confined to the 
proximal duodenum (Lefebvre et al., 1993) as well as in acinar cells of the pancreas 
(Tomasetto et al., 1990; Lefebvre et al., 1996; Terada et al., 2001). TFF3 was found in 
goblet cells of the intestine and colon and in extremely small amounts in the stomach 
(Mashimo et al., 1995). 
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Furthermore, embryonic development of the mouse demonstrated that while the 
expression of the TFF genes is highly dynamic, their distribution generally follows 
morphological boundaries and reflects the development of the tissue in which they are 
expressed. TFF expression is developmentally controlled in the GI tract and precedes 
mucous cell differentiation in several tissues (Otto and Patel, 1999). 
 
 
1.4.3  Expression of trefoil peptides under pathological conditions 
 
TFF1 was originally isolated from human breast carcinoma cell lines (Masiakowski et 
al., 1982). Since this discovery, several studies have documented an association 
between trefoil peptides and human epithelial malignancies. 
Table 3 summarises selective data regarding expression of human trefoil peptides in 
carcinomas of different organs. 
 
TFF1 was found to be expressed in a variety of other carcinomas including those of the 
pancreas (Collier et al., 1995; Welter et al., 1992), lung (Higashiyama et al., 1994), 
endometrium (Henry et al., 1991), ovary (particularly mucinous carcinoma; Dante et al., 
1994), prostate (Bonkhoff et al., 1995), gall bladder (Seitz et al., 1991), colorectum 
(Labouvie et al., 1997; Welter et al., 1994), skin (Hanby et al., 1998), and oesophagus 
(Labouvie et al., 1999). In breast carcinoma, TFF1 expression can be detected in more 
than 50% of the tumours and is significantly associated with oestrogen receptor 
expression (Pallud et al., 1993; Rio et al., 1987; Skilton et al., 1989), responsiveness to 
hormone therapy (Henry et al., 1990), and favourable prognosis (Cappelletti et al., 
1992; Foekens et al., 1990). 
Interestingly, TFF2 is not expressed in breast carcinomas (Tomasetto et al., 1990), but 
TFF3 expression is induced in breast carcinomas in a hormone (by oestrogen; May and 
Westley, 1997) dependent manner (Poulsom et al., 1997). 
 
The expression of TFF1 is lower in gastric adenomas and carcinomas than in adjacent 
normal gastric mucosa and hyperplastic polyps (Machado et al., 1996a), and its 
expression was observed in a frequency ranging from 48-66% (57%-Luqmani et al., 
1989; 56%-Henry et al., 1991; 48%-Muller and Borchard, 1993; 66%-Machado et al., 
1996b). Expression has been found to correlate with diffuse morphology of the stomach 
or with tumour development (Machado et al., 1996), and one series showed a 
significant relationship between TFF1 expression and tumour stage (Muller et al., 1993). 
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TFF3 expression in carcinomas is reflected in a small number of studies. 
Immunoreactive expression has been reported to occur in enterocytes in colonic 
adenomas and carcinoma, with significant associations among TFF3 expression and 
the degree of differentiation and mucin presence (Taupin et al., 1996). It has also been 
detected in skin mucinous carcinoma (Hanby et al., 1998), as well as in breast 
carcinoma (Theisinger et al., 1996; Poulsom et al., 1997) and is co-expressed with 
TFF1 (Poulsom et al., 1997). 
 
TFF2 expression in human carcinomas has been reported in squamous cell carcinoma 
of the oesophagus (Labouvie et al., 1999), of the gastric (Theisinger et al., 1991; 
Machado et al., 2000), and biliary tract (Seitz et al., 1991), and pancreatic carcinoma 
(Welter et al., 1992). 
 
 
Table 3: Expression sites of human trefoil peptides in carcinomas of different organs, as well as in 
different types of putative preliminary phases. 
 
Trefoil peptide Organ / Site Description References 
TFF1 Oesophagus Barrett’s metaplasia, 
Carcinoma 
Hanby et al., 1994; Labouvie et al., 
1999 
 Stomach Carcinoma: 
diffuse > intestinal 
Luqmani et al., 1989; Henry et al. 
1991; Theisinger et al., 1991 
 Small intestine Gastric metaplasia Hanby et al., 1993; Khulusi et al., 
1995 
 Large intestine Hyperplastic polyps, 
Adenoma, Adenocarcinoma 
Hanby et al., 1993; Welter et al., 
1994; Labouvie et al. 1997 
 Pancreas Carcinoma Welter et al., 1992; Collier et al., 1995
 Breast Carcinoma Foekens et al, 1990; Cappelletti et al., 
1996; Poulsom et al., 1997 
TFF2 Oesophagus Barrett’s metaplasia, 
Carcinoma 
Hanby et al., 1994; Labouvie et al., 
1999 
 Stomach Carcinoma Theisinger et al., 1991; Machado et 
al., 2000 
 Gall bladder Carcinoma Seitz et al., 1991 
 Pancreas Carcinoma Welter et al., 1992 
TFF3 Large intestine Hyperplastic polyps, 
Adenoma, Carcinoma 
Hanby et al., 1993; Taupin et al., 1996
 Breast Carcinoma Theisinger et al., 1996; Poulsom et 
al., 1997 
 Skin Mucinous carcinoma Hanby et al., 1998 
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In addition to their expression in carcinomas, trefoil factors are also expressed in a wide 
variety of ulcerative conditions of the GI tract, such as Barrett’s oesophagus (Hanby et 
al., 1994; Labouvie et al., 1999), a model of gastric ulceration in the rat (Alison et al., 
1995), and in duodenal ulcers (Hanby et al., 1993a; Khulusi et al., 1995). Both TFF1 
and TFF2 showed an expression pattern resembling that of the native gastric 
epithelium. Furthermore, they were found also in the small and large intestine in Crohn’s 
disease (Wright et al., 1990a; Wright et al., 1993), which only can serve to underscore 
their importance as molecules involved in the repair of gastrointestinal mucosa. 
In hyperplastic polyps and adenomas of the colon, all three trefoil peptides have been 
detected (Hanby et al., 1993c; Taupin et al., 1996), but only the TFF1 peptide could be 
demonstrated immunohistochemically, whereas both TFF2 and TFF1 showed mRNA 
within the polyps. 
 
To summarise, although trefoil peptides in human and other mammals are expressed in 
a tissue-specific manner within the normal GI tract (major site of expression), the 
situation is somewhat different in the case of damage to the GI tract and other organs, 
respectively. The biological role of these peptides in tumorigenesis is less clear. 
Experimental evidence for a role in tumour suppression comes from studies using 
knockout mice lacking the TFF1 gene (Lefebvre et al., 1996). All such animals 
developed antral adenomas and 30% of them developed carcinomas. Whether the 
TFF1 gene acts directly in tumour suppression at a genetic level or indirectly via 
maintenance of normal mucin production remains to be ascertained. However, a study 
of trefoil expression in the developing gut of the rat established that trefoil peptides are 
early markers of epithelial cell maturation, thus, suggesting a possible role for these 
peptides in gut epithelial cell differentiation (Familari et al., 1998). 
 
 
1.5  Function of trefoil peptides 
 
A functional characterisation of trefoil peptides was first carried out with native purified 
porcine TFF2 (Jørgensen et al., 1982). The availability of this peptide enabled several 
studies of the function of pTFF2, e.g. aiding in peristaltic movement (Jørgensen et al., 
1982b). However recent studies on the human and porcine peptides have not supported 
these earlier findings (McKenzie et al., 1997; Playford et al., 1995). 
 
With the production of recombinant trefoil peptides by E. coli or yeast (Thim et al., 
1995), extensive characterisation of trefoil peptide function was made possible. 
  Introduction 
 17
The close association of TFF expression with mucous secreting cells also suggested 
that trefoil peptides could possibly be important for the stabilisation of the mucous lining 
of the GI tract (Kindon et al., 1995). Although the physiological functions are not 
completely understood, there is growing evidence, both in vitro and in vivo, which 
supports the participation of TFFs in maintaining a normal mucosal barrier (protection) 
and reconstitution / wound healing (Mashimo et al., 1996; Playford et al., 1996). For 
example, when TFF1 are co-packaged within mucous cell granules (Wright et al., 1993), 
the stimulation of restitution by TFF2 is enhanced in a cooperative fashion by the 
addition of mucin glycoproteins purified from the intestine of either rat or man and 
achieve up to a fifteen-fold enhancement in restitution (Dignass et al., 1994) or uptake 
of oral trefoil peptides (recombinant hTFF2 and rTFF3) protect against ethanol- and 
indomethacin-induced gastric injury in rats (Babyatsky et al., 1996). Another in vivo 
study showed that the upregulation of trefoil expression is prominent during the repair 
phase after injury (Itoh et al., 1996). 
In general, over-expression of trefoil peptides in the GI tract is most often found in 
connection with ulceration and particularly in epithelial cells migrating across the base of 
such lesions (UACL, see below; Wright et al., 1990; Rio et al., 1991; Wright et al., 
1993). 
 
In various chronic ulcerative conditions in man, glandular structures develop within the 
mucosa derived from the ulcer associated cell lineage (UACL)(Wright et al., 1990b). 
These UACL glands display an up-regulation of all trefoil peptides (Hauser et al., 1993; 
Wright et al., 1990a). They express EGF (Wright et al., 1990), TGF-α (Ahnen et al., 
1991) and lysozyme (Stamp et al., 1992), all of which are potentially able to contribute 
to the healing process. In fact, local goblet and endocrine cell types may also be 
recruited to secrete TFF1 into the local environment (Wright et al., 1993). It seems that 
this lineage, budding out from bases of crypts adjacent to ulcers, plays a key role in the 
restoration of mucosal integrity. 
 
With regard to the association with growth factors, there is some evidence for synergism 
in intestinal mucosal protection between the trefoil peptides and growth factors, 
including EGF and fibroblast growth factor (Szabo et al., 1994). Experiments point to a 
synergy between rTFF3 and EGF resulting in better protection against indomethacin-
induced gastric damage (Chinery and Playford, 1995). 
 
Studies on mouse breast carcinoma cell lines transfected with human TFF1 cDNA have 
also indicated that the peptide has the ability to effect morphogenesis, causing the cells 
to grow as branched rather than spheroid structures in collagen gels (Williams et al., 
1996). This might be induced by rapid phosphorylation of β-catenin and the down-
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regulation of adhesion molecules, particularly E-cadherin (Hanby et al., 1996; Liu et al., 
1997). TFF2 also promotes branching morphogenesis in MCF-7 cells (Lalani et al., 
1999). 
 
Moreover, TFF2 and TFF3 act as motogens, and are able to promote epithelial cell 
migration when cell monolayers are wounded in a TGF-β independent manner (Dignass 
et al., 1994; Playford et al., 1995). 
Besides the protection of mucosa and restitution after epithelial damage, TFFs have 
been shown to inhibit apoptosis (Chen et al., 2000; Kinoshita et al., 2000; Lalani et al., 
1999; Taupin et al., 2000). 
 
The mechanisms by which trefoil peptides exert their main functions – gastric and 
intestinal protection and healing – have formed the subject of several articles (e.g., 
Poulsom, 1996; Sands and Podolsky, 1996; Plaut, 1997; Podolsky, 1997; Wright, 2001) 
 
One of the theories on how protection is accomplished maintains that trefoil peptides, 
together with mucin glycoproteins, form stable gel complexes (Thim, 1994). Indeed, a 
strong association exists between the expression of TFF and mucins, which both 
contribute to mucosal defence. In general, TFF1 is associated with MUC5AC 
expression, TFF2 with MUC6, and TFF3 with MUC2 (Longman et al., 2000). Several 
trefoil motifs in X. laevis are encoded by genes that also bear mucin core sequences 
(Hauser and Hoffmann, 1992). In mammals, however, no such homologues are known 
thus far. 
It has been also suggested that the interaction between TFF2 and mucin inhibits, both 
in vivo and in vitro, proton permeation through the mucus layer (Tanaka et al., 1997). In 
fact, the addition of TFFs to purified mucin preparations leads to a rapid increase in 
optical density and viscosity (Sands and Podolsky, 1996). The three dimensional 
structure of the trefoil domain also contains a binding pocket that may accumulate the 
sugar side-chain of mucin glycoprotein (Gajhede et al., 1993; De et al., 1994). When 
considering the in vitro study by Dignass et al. (1994), in which the motogenic effect of 
trefoil peptides could be enhanced by mucin (motogenic effect demonstrated for TFF1; 
Williams et al., 1996) and the fact that mucins and trefoil peptides are produced in the 
same cells and often up-regulated simultaneously upon injury (Wright et al., 1993; 
Longman et al., 2000), the hypothesis that these components act together to protect 
and heal the GI tract seems well-founded. However, it should be emphasised that no 
direct proof of such a complex formation has yet been established. 
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Another hypothesis aimed at explaining the function of trefoil peptides concerns their 
binding to extracellular receptors. The presence of basolateral receptors which mediate 
the action of trefoil peptides has been claimed (Chinery et al., 1993; Chinery and Cox, 
1995; Frandsen et al., 1986). While some reports illustrate the binding of trefoil peptides 
to GI membrane proteins of different sizes (Tan et al., 1997; Thim and Mortz, 2000), 
they were unable to determine, whether these receptor were significant on a functional 
level. 
 
In accordance with this theory, TFFs provoke actions in vitro quite similar to a receptor 
mediated response. For instance, application of TFF3 to epithelial cells leads to 
phosphorylation of β-catenin on tyrosine within 10 seconds (Chinery and Cox, 1995). 
The well-known growth factor, EGF, also phosphorylates β-catenin, and during this 
process, recombinant rTFF3 causes tyrosine phosphorylation of the EGF receptor itself 
(Efstathiou et al., 1998). This finding has also been confirmed (Taupin et al., 1999). This 
activation, however, does not appear to be direct, suggesting that TFF3 enhances cell 
migration through modulation of E-cadherin/catenin complex function (Liu et al., 1997). 
Furthermore, TFF3 has been shown, again in vitro, to decrease extracellular signals 
related to protein kinase (ERK) activity and the mitogen activated protein kinase 
(MAPK) pathway, probably through induction of a tyrosine phosphatase (Kanai et al., 
1998). 
 
Although trefoil peptides seem to play an important role in the defence of the GI tract 
(Plaut, 1997), other protective factors such as immunoglobins, cytokines, and growth 
factors must be taken into consideration, when evaluating the overall defence 
mechanism (Podolsky, 1997; Cook et al., 1999; Wong et al., 1999). 
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1.5.1  Transgenic and knockout studies 
 
The possibility of inserting DNA from any source directly into the mouse was first 
demonstrated by Gordon et al. (Gordon et al., 1980), who devised the strategy of 
pronuclear microinjection. Studies for knockout models were performed a few years 
later (Lin et al., 1985; Thomas and Capecchi, 1987). 
 
Three transgenic and knockout models were generated for studying the possible 
function of trefoil peptides. To explore the function in the mucosal repair process, a 
transgenic mouse overexpressing human TFF1 specifically in the villi of the jejunum 
was constructed (Playford et al., 1996). In this model, a marked difference in the 
amount of damage caused by indomethacin compared with the controls was found, 
thus, supporting the data assumption that trefoil peptides play an essential role in 
stimulating the gastrointestinal repair process (Playford et al., 1996). 
 
An additional question concerns the degree to which TFF1 plays an autocrine role in the 
development of mammary tumours (approximately 50% of human breast tumours 
produce TFF1). Those transgenic mice which overexpressed human TFF1 and secreted 
it into milk did not seem to have any mammary gland dysplasia, and TFF1 expression 
had no cognisable effect upon the physiology and/or development of the suckling young 
or the transgenic mother (Tomasetto et al., 1989). 
 
In a study of mice overexpressing TGF-α in the gastric mucosa, a marked increase in 
the mucosal surface cells producing murine Tff1 was observed (Goldenring et al., 
1996). When TGF-α was knocked out (Cook et al., 1997), the normal increase in trefoil 
peptide expression following gastric ulceration was not detected, indicating that 
induction of trefoil peptide expression after injury depends on the presence of TGF-α 
(Cook et al., 1997). 
 
In the last two studies the genes encoding Tff1 and Tff3, respectively, were deleted by 
gene-targeting techniques (refer to 1.6). 
Disruption of the Tff1 gene (Lefebvre et al., 1996) did not affect Tff3 expression. In 
contrast, Tff2 expression was not detected in the Tff1-/- stomach samples but was 
detected in the Tff1-/- pancreas samples (Lefebvre et al., 1996), indicating coordinated 
expression of Tff1 and Tff2 in the stomach as already suggested after their genomic 
analysis (Gött et al., 1996). According to this model, the absence of Tff1 did not seem to 
be compensated by increased expression of the other trefoil peptides. The mice lacking 
Tff1 showed adenomatous hyperplasia in the antropyloric part of the stomach, and after 
five months, 30 % of them developed multifocal intraepithelial or intramucosal 
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carcinomas. The small intestine was characterised by enlarged villi and an abnormal 
infiltrate of lymphoid cells. These results prompted researchers to suggest that apart 
from being responsible for normal differentiation of the antral and pyloric gastric 
mucosa, TFF1 may also function as a gastric-specific tumour suppressor gene. 
However, further studies are needed to fully evaluate this suggestion. 
 
In the other gene knockout experiment, mice lacking Tff3 had impaired mucosal healing 
and died from extensive colitis after oral administration of dextran sulfate (Mashimo et 
al., 1996). The Tff3-/- suffered from poor epithelial regeneration after injury. In contrast, 
gastric genes Tff1 and Tff2 showed reduced expression, once again suggesting that 
trefoil peptides may individually regulate transcription of the entire family (Taupin et al., 
1999).  
In addition, luminal administration of recombinant TFF3 to the Tff3-/- mice resulted in 
normal healing; a clever proof for the protective role of TFF3 in maintaining a normal 
mucosal barrier. Ultimately, these findings demonstrate that TFF3 is a factor that 
participates in healing and repair mechanisms in the intestinal mucosa (Mashimo et al., 
1996). 
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1.6  Gene targeting 
 
Mice are increasingly being used as models for the study of various human diseases. 
This is primarily because among mammalian models, they are most amenable to 
genetic manipulations. 
Until recently, mutants were produced by mutagenesis followed by selection for a 
particular phenotypic change. Gene targeting by homologous recombination is an 
especially effective technique in generating mouse strains with defined mutations in 
their genome. These genetically modified, 'designer' animals permit us to ask questions 
about elaborate and complex biological systems (Mansour, 1990; Zimmer, 1992). 
 
Two key technologies have facilitated this experimental system. First, the isolation of 
embryonic stem (ES) cells were isolated as permanent in vitro cell lines (Evans and 
Kaufman, 1981; Martin, 1981) that can repopulate the blastocyst embryo and possess 
the capacity to contribute to the germline tissue of mice (Bradley et al., 1984). Second, 
mammalian cells were found to recombine introduced vector DNA with a homologous 
chromosomal target. The possibility of homologous recombination between foreign DNA 
and existing homologous sequences in the mammalian genome was studied from the 
beginning of the 1980s, and evidence was presented by two groups in 1985 (Lin et al., 
1985; Smithies et al., 1985). Mutations introduced into these cell lines were transmitted 
to the offspring (Doetschman et al., 1987; Robertson et al., 1986). Thereby, the concept 
of ‘designer’ mutations became a reality. 
 
The process of generating ‘knockout’ animals demands several key steps to obtain 
animals in which both alleles of the gene of interest are non-functional (Galli-Taliadoros 
et al., 1995). 
 
Gene targeting in mice involves: 
 
• Engineering a gene targeting construct 
• Transfection of embryonic stem (ES) cells 
• Assessing ES cells for homologous recombination and screening 
• Generating chimeric mice by blastocyst injection 
• Breeding chimeric mice to homozygosity 
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1.6.1  Engineering a gene targeting construct 
 
The first step toward a construct design involves the availability of a genomic clone or 
sequences containing the gene of interest. Two basic configurations of constructs are 
used for homologous recombination: insertion constructs and replacement constructs. 
 
The insertion construct contains a region of homology to the target gene cloned as a 
single continuous sequence and is linearised by cleavage of a unique restriction site 
within the region of homology. Homologous recombination introduces the construct into 
the homologous site of the target gene and interrupts it by adding sequences. This 
leads to gene duplication, with the marker gene as well as the plasmid DNA being 
inserted. While similar or higher gene targeting efficiency has been achieved using this 
strategy in comparison to the replacement construct (see below)(Deng and Capecchi, 
1992; Hasty et al., 1991a), it has not been adopted for knockouts. As a result, the 
normal gene can be regenerated from the mutated target gene by a random 
intrachromosomal recombination event. This phenomenon was used to create a new 
method termed the 'hit and run' procedure (duplications, with subtle mutations, are 
introduced into the target gene and then removed ; Hasty et al., 1991b). 
 
The replacement construct is the more commonly used construct. It contains two 
regions of homology to the target gene, located on either side of a positive selectable 
marker, the plasmid DNA sequences, and a linearisation site outside of the homologous 
sequences of the vector (Fig. 4). Nearly all constructs rely on the positive selection of an 
antibiotic resistance gene (e.g., neomycin or neor)(Thomas and Capecchi, 1987). 
This insertion serves a dual purpose: it interrupts the targeted gene and provides a tool 
for selection. In some cases, a negative selectable marker may also be used to enrich 
the transfected cells against random integration events (Mansour et al., 1988). 
Homologous recombination proceeds by a double cross-over that replaces the 
homologous target gene sequences with the replacement construct sequences. Any 
heterologous sequences at the ends of the vectors are excised from the vector and are 
not recovered as stable genomic sequences in the recombinant allele following 
targeting. 
Because no duplication of sequences occurs, the normal gene cannot be regenerated. 
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Figure 4: A replacement targeting construct. Production, selection, and identification of targeted gene 
disruption by homologous recombination. An example of a restriction enzyme site (RE) and hybridisation 
probe that can be used to identify cells in which homologous recombination has occurred (shaded) is 
shown (E: endogenous, HR :homologous recombinant). Adapted after Mortensen (2000). 
 
 
The DNA used to construct the targeting vector must be from the same species as the 
cell in which the mutation is introduced. It should also be isogenic with the target cell 
(this is not absolutely required, but increases the probability of success), because 
animal strains may differ just as individual outbred animals differ. A single DNA 
mismatch is sufficient to decrease the rate of homologous recombination (Deng and 
Capecchi, 1992; Te Riele et al., 1992). 
  Introduction 
 25
Cre-loxP system 
To study genes which are essential for murine development and therefore, lethal if 
disrupted, a system was developed, in which such genes can be inactivated in a tissue 
or cell-specific manner (Gu et al., 1993; Gu et al., 1994). This technique is based on the 
Cre-loxP recombination system of the bacteriophage P1 (Sternberg et al., 1986). Cre 
recombinase is an enzyme which catalyses the site specific between the 34-bp motifs 
termed loxP site. If two loxP sites in the same orientation next to each other exist, Cre 
can act to loop out the sequence between the two sites, leaving a single loxP site in the 
original DNA and a second loxP in a circular piece of DNA, containing the intervening 
sequence. 
Thus, a properly designed targeting construct containing loxP can be used either for 
introducing subtle mutations or for a temporally or spatially controlled knockout (Sauer, 
1993). 
 
 
1.6.2  Transfection of embryonic stem (ES) cells 
 
Embryonic Stem Cells 
Gene targeting is achieved in murine embryonic stem (ES) cells. ES cells are derived 
from 3.5 days postcoitum (dpc) mouse embryos and arise from pluripotent, 
uncommitted cells of the inner cell mass (ICM), the part of the mouse blastocyst that 
usually gives rise to the embryo proper (Evans and Kaufmann, 1981; Martin, 1981). 
 
 
Figure 5 : Early development stages of the mouse (by D. Leja, NHGRI). 
 
 
The ES cells can grow in vitro and retain the potential to contribute extensively to all of 
the tissues, including the germline tissue of an animal, when injected back into a host 
blastocyst, which is allowed to develop in a surrogate mother. 
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In the vast majority of these gene targeting experiments, ES cells derived from “129 
mouse” substrains are an essential component (Galli-Taliadoros et al., 1995; Simpson 
et al., 1997). The most common method for introducing DNA into ES cells is by 
electroporation (Fig. 4)(Thomas and Capecchi, 1987). 
 
 
1.6.3  Assessing ES cells for homologous recombination and screening 
 
Not all ES cells actually take up the targeting construct. Those that do can be identified 
by growing cells in the selective medium (Fig. 4). A small proportion of integration may 
occur by homologous recombination, precisely at the endogenous counterpart of the 
transfected DNA. 
To be sure, one of the most important aspects of any gene targeting experiment is to 
confirm that the desired genetic changes have occurred. Following the transfection of a 
replacement vector, colonies which survive selection should be clonally isolated and 
screened by PCR and Southern blot analysis for a specific recombination allele. First, a 
PCR-based screening for the rapid detection of candidate targeted colonies was 
performed (Kim and Smithies, 1988), followed by a second screening to verify the 
correct targeting by Southern blot analysis (Fig. 4). 
 
 
1.6.4  Generating chimeric mice by blastocyst injection 
 
The determining factor in the production of a gene knockout mouse strain is the 
generation of ES cell embryos that transmit the desired alteration to the next generation. 
Until recently, chimeric mice were almost exclusively produced by injection into the 
blastocyst of ES cells displaying the desired genotype and subsequently introduced into 
pseudo-pregnant recipient females (techniques are described in detail in Joyner, 2000; 
Fig. 6). 
After blastocyst injection, ES cells become incorporated within the developing ICM of 
the embryo and contribute to the development of different (chimeric) embryonic 
lineages, in competition with host cells.  
Most ES cell lines have an XY/male genotype (female derived XX cell lines are reported 
to be unstable). This has two advantages. First, XY ES cell lines, when injected into 
female/XX blastocysts, tend to bias the development of the resulting chimera toward a 
male phenotype (Iannaccone et al., 1985). In male chimeras, only XY-bearing germ 
cells (i.e., those derived from the ES cells) will form functional gametes. XX primordial 
germ cells (i.e., those derived from the host blastocyst) will not form functional gametes 
and are lost. Therefore, the development of gametes derived from the ES cells is 
favoured. 
  Introduction 
 27
Second, a male chimera can produce more offspring over its reproductive life span 
(~1.5 years) than a female (~8 litters), so that even chimeras with low percentage 
contribution of ES cells to the germline can be detected. 
 
 
Figure 6: Production of a chimeric mouse. ES cells (green at top left) are isolated from an agouti mouse 
strain and altered to carry a targeted mutation (m) in one allele (M: wild-type allele). The ES cells are then 
injected into blastocysts. The embryos are transferred into surrogate mothers. Newborn chimeras indicate 
that the ES cells have survived and proliferated. A represents agouti, a black. Adapted after Griffiths et al. 
(1999). 
 
 
1.6.5  Breeding chimeric mice to homozygosity 
 
Most ES cell lines are derived from the “129 mouse” substrains (e.g., 129/J, 129/Sv). 
When injected into embryos of the C57BL6/J strain, the 129 ES cells tend to 
predominate in the chimeras (Schwartzberg et al., 1989), thus affecting the likelihood 
that the ES cells will contribute to the germline. The most practical and readily apparent 
genetic marker of chimerism is coat colour. Most of the 129 ES cells have an agouti 
coat colour genotype (besides pink-eyed chinchilla for 129/Ola & 129/J and light 
chinchilla/albino for 129/SvJ; Simpson et al., 1997), whereas that of C57BL6/J embryos 
is black. Therefore, the chimeric mice produced from this combination will display a 
colour mix of agouti/black (Fig. 6 and 37), which provides strong evidence for the 
survival of ES cells in the embryo. 
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Figure 7: Breeding scheme to obtain homozygous mutant (m) animals. Chimeric males are mated to 
C57BL6/J female. Litters are screened for evidence of the targeted mutation (m) (green in inset). Males 
and females (concentric box) carrying the mutation are mated to one another to produce F2-mice whose 
cells carry the mutation (m/m) in both alleles (knockout animal in a curly-tail phenotype). Such animals 
(box on the right) are characterised by genomic analysis of their tail DNA. A represents agouti, a black 
and M wild-type allele. Adapted after Griffiths et al. (1999). 
 
 
Only some of the animals carry the targeted gene in their germline. The criterion, for 
being able to transmit the ES genotype through the germline, is that more than 50% of 
the offspring born should be chimeric. Thus, chimeric males are generally test bred to 
ascertain contribution of the ES cells to germline (Fig. 7). A good test breeding scheme 
for this common combination is to breed chimeras back to C57BL6/J mice. Agouti 
animals are derived from the 129 ES cells and will be 129xC57BL6/J F1 (Fig. 7, centric); 
non-agouti animals will be pure C57BL6/J.  
If test breeding is done, the first available heterozygous animals are likely to be F1 mice 
between two inbred strains (a 129 substrain and C57BL6/J). These mice will be 
genetically uniform except for the targeted allele and any alleles that were segregating 
in the 129 substrain from which the ES cells were derived (Simpson et al., 1997). Once 
they have been characterised by Southern blot analysis of the tail DNA, heterozygotes 
for the targeted allele can be mated together (Fig. 7, centric box) to produce F2 litters 
representing wild-type, heterozygous, and homozygous mutant animals. 
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Once a suitable breeding scheme is established for maintaining the mutation and the 
timing of any mutant effect, the challenge is to determine the cause of phenotypic 
effects, whether they are mild or severe. 
The more is known about the biological function of the gene and its expression pattern, 
the easier it is to predict possible causes of any given phenotype. Histological analysis 
and gene marker analysis at embryonic or later stages (prior to death) can then be used 
to characterise the progression of the defect and in a causal way. 
 
 
1.7  Aims of the project 
 
The creation of knock-out / transgenic mice is of major interest to understanding the 
function of the TFF peptides. 
At the beginning of this work Tff1 and Tff3 knockout mice had been constructed, but a 
Tff2 null-mouse did not exist. Mice lacking Tff1 showed decreased gastric mucus 
production, all developed gastric adenomas, and 30% of them developed multifocal 
intraepithelial or intramucosal carcinomas. At the same time Tff3-/- mice revealed a 
normal phenotype, but exhibited impaired mucosal healing and died from extensive 
colitis after oral administration of dextran sulfate sodium (Lefebvre et al., 1996; 
Mashimo et al., 1996). Remarkably, the expression of Tff2, which is normal in stomach, 
duodenum, and pancreas was not detected in the stomach samples of the Tff1-/- mice 
(Lefebvre et al., 1996). 
The present work was elaborated in order to elucidate the function of Tff2 in vivo. 
Therefore, the primary object was first the construction of a targeting vector to knockout 
the Tff2 gene and second the characterisation of this gene targeting event in 
heterozygous (Tff2+/-) mice. 
 
For basic information of this project, the genomic structure of the mouse Tff gene cluster 
needed to be determined. Since the three known human genes are clustered in 21q22.3 
(Gött et al. 1996), a similar arrangement in a homologous region of the mouse was to 
be expected. All three Tff genes were described (Lefebvre et al. 1993; Tomasetto et al., 
1990; Mashimo et al., 1995) and the mouse Tff3 gene was mapped to 17q by FISH 
(Burmeister and Meyer, 1997; Chinery et al., 1996b). 
To investigate this arrangement, four genomic recombinants were aligned into a contig 
and analysed in detail by restriction mapping and long range PCR. 
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2. Material 
 
 
2.1  Enzymes and reaction kits 
 
[α32P] dCTP            ICN, Eschwege, D 
CIAP (calf intestine alkaline phospatase)  Roche Molecular Biochemicals, Mannheim, D 
DNA Sequencing Kit         Perkin Elmer, Weiterstadt, D 
Amersham Pharmacia, Freiburg, D 
Expand™ Long Template PCR System   Roche Molecular Biochemicals 
Jetstar Plasmid Purification Kit      Genomed GmbH, Bad Oeynhausen, D 
Klenow enzyme           Roche Molecular Biochemicals 
pGEM®-T Vector System I       Promega, Mannheim, D 
Proteinase K            Merck, Darmstadt, D 
QIAquick Gel Extraction Kit       Qiagen, Hilden, D 
Random Primed Labelling Kit      Roche Molecular Biochemicals 
Restriction endonucleases       NEB, Franfurt, D; Takara, Taufkirchen, D; 
                Roche Molecular Biochemicals 
                MBI Fermentas, St.Leon-Rot, D 
T4 DNA Ligase           Roche Molecular Biochemicals 
Taq-Polymerase            Promega, Mannheim, D 
 
 
 
2.2  Chemicals 
 
 
The chemicals included in these various studies were purchased from different companies, 
such as Merck, Sigma-Aldrich, ICN, Difco, Roth, Pharmacia, Roche, Biomol, or Bio-Rad. 
 
 
 
2.3  Vectors 
 
pL2-neo kindly provided by Prof. Dickson, ICRF, 
London, UK 
pBK-CMV Stratagene, Amsterdam, NL 
pGEM-T® Promega, Mannheim, D 
 
 
 
2.4  Filter, membranes, columns, film material, tubes 
 
0.2 ml PCR-stripes Biozym, Hess. Oldendorf, D 
12-ml tubes Greiner, Frickenhausen, D 
Butterfly membrane Schleicher&Schuell, Dassel, D 
Developing cassette Siemens, Nixdorf, D 
Eppendorf tubes (0.5 ml and 1.5 ml) Eppendorf, Hamburg, D 
Falcon tubes (50 ml) Greiner 
Fuji Medical X-ray film RX Hirrlinger, Baden-Baden, D 
Kodak GBX Developer Hirrlinger 
Kodak GBX Fixer and Replenisher Hirrlinger 
Mitsubishi Video Copy Processor Hirrlinger 
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Nitrocellulose filter, 0.45 µm Nalgene, Rochester, NY, USA 
Nitrocellulose filter, 0.22 µm Schleicher&Schuell 
Nylon membrane, Nytran N Schleicher&Schuell 
Parafilm American National Can™, Menasha, WI, USA 
Storage phosphor imaging screen plus  
exposure casette 
Bio-Rad, Munich, D 
Whatman 3MM paper Whatman, Maidstone, UK 
 
 
 
2.5  Instruments 
 
Biofuge 15 R Heraeus, Osterode, D 
Electrophoresis apparature Gibco BRL, Karlsruhe, D 
Electroporation System ECM 399  
(and cuvettes) 
BTX, San Diego, CA, USA 
Gel Documentation System LTF Labortechnik, Wasserburg, D 
Gel-Dryer Model 583 Bio-Rad, Munich, D 
Heat block Barnstead, Dubuque, IA, USA 
Heating plate Bachofer, Reutlingen, D 
Hybridisation oven Bachofer 
Incubator Bachofer 
LKB 2015 pulsator electrophoresis unit Pharmacia 
Micro centrifuge Eppendorf, Hamburg, D 
Microwave Siemens 
Mini centrifuge Roth 
Personal Molecular Imager FX BioRad 
Photometer LKB-Pharmacia 
Shaker Pharmacia 
Shaker-incubator Bachofer 
Sorvall-Centrifuge RC-5C DuPont, Newton, CT, USA 
Sterile bench BDK, Sonnenbühl, Genkingen, D 
Thermocycler, PCR  Biozym PTC-100 / PTC-200 
Hybaid, Heidelberg, D 
Perkin Elmer 9600, Rodgau-Jügesheim, D 
UV-Stratalinker™ 1800 Stratagene 
UV-Table LTF-Labortechnik 
Vacuum Concentrator Bachofer 
Water bath B. Braun, Melsungen, D 
 
 
 
2.6  Computer software, Internet 
 
• NCBI (GenBank): http://www.ncbi.nlm.nih.gov/ 
• European Bioinformatics Institute (EBI): http://www.embl-ebi.ac.uk/ 
• The Jackson Laboratory: http://www.jax.org/ 
• Mouse Genome Database: http://www.informatics.jax.org/mgihome/ 
• Primer: http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi 
• DNAsis (Hitachi Software Engineering) 
• Quantity One for Personal Molecular Imager FX (Bio-Rad, Munich, Germany) 
• Gel documentation analyse software “Bio 1D” (LTF, Wasserburg, Germany) 
• Paint Shop Pro 5 / MS Office 
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2.7  Oligonucleotides 
 
 
The oligonucleotides (primer) syntheses were made by following companies: 
 
• MWG-Biotech, Ebersberg, D 
• Gibco BRL, LIFE Technologies, Karlsruhe, D 
• BIG-Biotech, Freiburg, D 
 
 
Table 4: List of primer pairs for PCR and primers for sequencing (f-r-for-rev refer to forward and reverse - 
orientation of the primers). 
 
Name Sequence Anneal.- 
temp.: oC 
Purpose/characteristica
m2-pro 
m2-end 
TAGGTCTGCTCTTTAGAGCCTG
AAATGAAGCTTCCTTTCGGCAAC
59oC Tff2 gene locus 
ClaI-for 
BamHI-rev 
GGATCGATCCCCATCCCATACCC
CGGGATCCTATAGGGTCTGAGGTC
57 > 72oC  generation of restriction sites 
(bold) for target vector 
XbaI-for 
XbaI-rev 
GCTCTAGAGCCTGGGATGGGGC
GCTCTAGAGCCTGGACCGACAG
57 > 72oC  generation of restriction sites 
(bold) for target vector 
m2/251-for 
m2/1189-rev 
GGCACTGTGTGAGGGAAGTGA
AATCTGTCACCCTGCCTTTGTC
59oC  5’-flanking DNA including exon 
1 of Tff2 and a part of intron 1 
Tff2f 5’-flanking 
Tff2r intron1 
GGCACTGTGTGAGGGAAGTGA
AATCTGTCACCCTGCCTTTGTC
59oC  5’-flanking DNA containing 
exon 1 of Tff2 (P2*) 
Tff1f 5’-flanking 
Tff1r exon1 
TCCGCTCAGCTCTACCTGAG
CAGATCACCTTGTGCTCCATG
59oC  5’-flanking DNA containing 
exon 1 of Tff1 (P1) 
Tff3f 5’-flanking 
Tff3r 5’-UTR 
TGCTAGGCCCTGCTGCTGC
CAGGACCACTGCACAGGATG
59oC  5’-flanking DNA of Tff3 (P3) 
Tff1f 3’-UTR 
Tff2r 5’-flanking 
TGACACAGTTCAACCCCTCAG
GAGTCCATGACTCGGATACAG
59oC  distance between Tff1 and Tff2 
Tff2f 3’-UTR 
Tff3r 5’-flanking 
TTGGGAAGTCACCCTGAACTG
GAGTAAAGAGCCGAAGACAGG
59oC  distance between Tff2 and Tff3 
m2-pro 
m2-250rev 
TAGGTCTGCTCTTTAGAGCCTG
ATGCCCACCCATGAAATGCCC
61oC  PCR screening of BAC library 
(P2) 
Reko-for 
WT-rev 
GGTACCCCGGGTTCGAAATC
ACTGTGATCAGCAGTCATGCG
59oC  screening for homologous 
recombination 
Tff2ex2for 
WT-rev 
GTCCCYTGGTGTTTCCACCC
ACTGTGATCAGCAGTCATGCG
59oC  wild-type fragment (as a 
standard control) 
   
M13-for GTAAAACGACGGCCAGTGAATT 50oC sequencing of ligation boundary
M13-rev CAGGAAACAGCTATGACCATGA 50oC sequencing of ligation boundary
SP6-r pL2 GCCAAGCTATTTAGGTGACAC 50oC sequencing of ligation boundary
neo-rev TTGGGTGGGAAACATTCCAGGC 50oC sequencing of ligation boundary
SeqEco-r ACGAATTCCCCAGTGGCA 50oC sequencing of ligation boundary
Pst-m2-for GATTCTCTCAAGACCTGCT 50oC sequencing unknown data from 
5’-flanking DNA of Tff2 
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2.8  Bacterial cloning systems and bacteria stocks 
 
2.8.1  Bacterial Artificial Chromosomes (BACs) 
(Shizuya et al., 1992) 
BAC recombinants harbouring genomic mouse DNA from strain 129/Sv (new nomen-
clature: 129/S1; Simpson et al., 1997) were obtained from Research Genetics, 
Huntsville, AL, USA. Primers (m2pro/m2-250rev) were designed from genomic 
sequences (GenBank database accession No. U78770) to screen recombinants by 
PCR. This PCR product yielded 3 BAC recombinants. 
 
Facts about mouse BACs from CalTech:-http://informa.bio.caltech.edu/idx_www_tree.html- 
vector: pBeloBAC 11, 
               host: HS996, modified DH10B 
              average insert size: 130 kb 
 
 
Table 5 : Mouse BAC clones containing the trefoil genes obtained by PCR screening. 
 
BAC name insert size vector size 
123M10 97 kb 7.4 kb 
517E16 135 kb 7.4 kb 
566K2 150 kb 7.4 kb 
 
 
2.8.2  Bacteria strains 
 
In the context of this work following strains were used: 
 
 E. coli XL1-Blue MRF´strain: 
∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
[F´proAB lacIqZ∆M15 Tn10 (Tetr)] 
Reference: Stratagene 
 
 SURE strain: 
e14– (McrA–) ∆(mcrCB-hsdSMR-mrr)171 endA1 supE44 thi-1 gyrA96 relA1 lac recB 
recJ sbcC umuC::Tn5  (Kanr) uvrC [F' proAB lacIqZ∆ (M15 Tn10 (Tetr)] 
Reference: Stratagene 
 
 GM 272 
Sex: F- 
Mutation: (fhuA2 or fhuA31) (lacY1 or lacZ4) (tsx-1 or tsx-78) glnV44(AS) galK2(Oc) 
LAM- dcm-6 dam-3 mtlA2 metB1 thi-1 hsdS21 
Reference: http://cgsc.biology.yale.edu/cgi-bin/sybgw/cgsc/Strain/12910 
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2.9  Gene targeting (“mouse”) facility  
 
The work with ES (embryonic stem) cells and their respective cell lines, blastocyst 
injections and mice breeding procedures (chimeras, heterozygous, and homozygous) 
were performed by colleagues (I. Rosewell et al.) from the ICRF at the Transgenic Lab 
in Clare Hall, UK. Upon establishment of the chimeric mice, the breeding programme 
was transferred to the ICSM at the Hammersmith Campus, London, UK. 
 
 
2.10  Media for bacteria 
 
• LB-(Luria Bertani) medium (modified) 
bacto Tryptone:    10 g 
bacto Yeast extract:  5 g 
NaCl:        5 g 
Glucose:       1 g 
Dissolve the above components in double distilled water. Adjust the volume to a liter 
and autoclave it. Cool the solution and add the appropriate amount of antibiotic just 
before use. Typically Ampicillin (for T/A-vector and the targeting vectors) at 100 µg/ml, 
Kanamycin (for the pBK-CMV vector) at 50 µg/ml or Chloramphenicol (for BAC-
recombinants) at 12.5 µg/ml. 
 
• LB agar 
Per one liter LB media (without glucose !) add 16 g Bacto agar and autoclave. 
 
• SOB medium (per liter) 
To 950 ml H2Odd, add: 
Bacto tryptone:    20 g 
Bacto yeast extract:  5 g 
NaCl:        0.5 g 
Shake until the solutes have dissolved and ad 10 ml of 250 mM KCl. Adjust the pH to 
7.0 with 5 N NaOH and the volume to 1 liter. Sterilise by autoclaving. Just before use, 
add 0.01 Vol. of 2 M MgCl2 (autoclaved). 
 
• SOC medium 
It’s identical to SOB, except it contains glucose. Before use add 0.01 Vol. of a sterile (by 
filtration through a 0.22µm filter) 2 M solution of glucose (final conc.: 20 mM) 
 
• X-gal for agar-plates 
Stock solution: 20 mg/ml in dimethylformamide (use a glass or polypropylene tube), 
should be wrapped in aluminium foil to prevent damage by light (stored at –20oC). 
 
• IPTG for agar-plates 
Stock solution: 100 mM (23,8 mg/ml) in 70% Ethanol (stored at -20oC). 
 
Before making the agar plates, add 2 ml of X-gal and 2 ml IPTG to 1 liter LB agar (after 
autoclave, allow it to cool to 50-55oC), if needed. 
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2.11  Buffers, solutions, and DNA markers 
 
Electrophoresis Buffers: 
• 10x TAE:  400 mM  Tris-HCl, pH 8.0 
50 mM    Sodium acetate 
10 mM    EDTA 
 
• 10x TBE:  890 mM  Tris-HCl 
 (pH 8.3)  890 mM   Boric acid 
25 mM    EDTA 
 
• Ethidium Bromide:   0.1 mg/ml in 1xTAE 
 
• 10 % APS: 
Place 1.0 g of ammonium persulfate (APS) into a tube and add distilled water to 10 
ml volume. Invert to dissolve the APS and store at 4oC for up to one week. 
 
• TE-Buffer: 10 mM   Tris-HCl 
(pH 8.0)  1 mM    EDTA 
 
• Gel-loading buffer (10x): 0.25 % bromphenol blue 
0.25 % xylene cyanol FF 
30 % glycerol in water (storage temperature: 4oC) 
 
Blotting solutions: 
• Depurination solution:  0.25 M   HCl 
• Denaturing solution:   0.5 M   NaOH 
• Transfer solution:    0.5 M   NaOH 
1.5 M   NaCl 
• Neutralising solution: 50 mM Phosphate buffer, pH 7.0 
50 mM Na2HPO4 (dibasic) titrated with 50 mM NaH2PO4 (monobasic) 
 
Hybridisation solutions: 
• Hyb-mix(ture), also called CHURCH buffer 
1 % BSA 
7 % SDS 
1 mM EDTA 
0.5 M Phosphate Buffer, pH 7.0 
Store on bench indefinitely. If room gets too cool, it will precipitate out. Simply heat it at 
65oC to redissolve.  
 
• Wash solution I:     2x SSC 
• Wash solution II:     2x SSC / 1 % SDS 
• Wash solution III:    2x SSC / 0.1% SDS 
 
• 20x SSC:       3 M   NaCl  
0.3 M  sodium citrate  
Mix, adjust pH to 7.0 with HCl, and store at 4oC  
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Isolation solutions: 
• 3 M Sodium acetate (NaAc), adjusted with acetic acid to pH 5.2 
 
• Ethanolabs (EtOHabs)  Isopropanol 70% Ethanol 
 
• E1 solution (cell resuspending) 
50 mM   Tris-HCl, pH 8.0 
10 mM   EDTA 
containing RNase: 100 µg/ml (stored at 4oC). 
 
• E2 solution (cell lysis) 
200 mM  NaOH 
1.0 %  SDS  
• E3 solution (neutralisation) 
3.1 M  potassium acetate 
 with acetic acid adjusted to pH 5.0 
 
 
Sequencing: 
• 5 % sequencing gel (36 cm glass plates): 
21.0 g    urea (7 M) 
8.4 ml    Acrylamide/Bis, 30% (29:1) 
6.0 ml    10x TBE 
20 ml    H2Odd 
350 µl    10 % APS 
15 µl     TEMED 
Buffer: 1x TBE  
 
Transformation solution: 
• DMSO 
• FSB-buffer:   10 mM   potassium acetate, 
      (adjusted to pH 7.5 with 2 mM acetic acid) 
45 mM   MnCl2 x 4H2O 
10 mM   CaCl2 x 2H2O 
100 mM  KCl 
3 mM   Hexaminecobalt chloride 
10 %   glycerol 
Sterilise the solution by filtration through a 0.45 µm (pore size) filter, dispense the 
solution into 50 ml aliquots and store at 4oC.  
 
DNA-Markers: 
• kb-ladder: (100 ng/µl):   20.0 µl stock solution (0.5 mg/ml) 
 (MBI Fermentas)      16.6 µl loading buffer 
           63.4 µl H2Odd 
 
• λ-HindIII marker: (50 ng/µl): 10.0 µl stock solution (0.5 mg/ml) 
 (MBI Fermentas)      16.6 µl loading buffer 
            73.4 µl H2Odd 
 
• PFGE marker: A mixture of λ-DNA-HindIII fragments and λ concatemers embedded 
(NEB)     in 1% LMP agarose and 1-2 mm discs are applied to gels. 
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3. Methods 
 
3.1  Electrophoresis and DNA recovery from agarose gel 
 
Agarose gel electrophoresis 
0.7-2.0% gels were prepared by melting 0.7-2.0 g agarose in the presence of 1xTAE 
until the solution was clear. Electrophoresis was carried out in a horizontal configuration 
(Gibco) at 10 V/cm for about one hour. 
 
Purification of DNA fragments using QIAquick Gel Extraction Kit 
Several reactions such as ligation, sequencing, or PCR require purified fragments. An 
easy way is gel separation and recovery from agarose gel. The QIAquick Gel Extraction 
Kit was used; the desired DNA fragment was excised from the agarose gel and treated 
following manufacturer’s protocol. 
 
 
3.2  Restriction endonucleases 
 
Restriction enzymes have the ability to recognise short DNA sequences and cut dsDNA 
at specific sequence dependent positions. Therefore, these proteins provide an 
essential tool in molecular biology. Generally these endonucleases are produced in 
bacteria and belong to a restriction/modification system.  
For this work several different enzymes from different suppliers for several studies 
(restriction analysis to confirm results, Southern blot, cloning,...) were used. 
 
 
3.3  PCR 
 
PCR is an abbreviation for Polymerase Chain Reaction first reported in the mid-1980s 
by Mullis and colleagues (Saiki et al., 1985; Saiki et al., 1988). The technique enables 
the amplification of a specific DNA region within a known DNA sequence. This is 
achieved by the use of (oligonucleotide) primers which are complimentary to the defined 
sequence of the DNA template. A DNA polymerase enzyme, in suitable conditions in 
the presence of dNTPs, catalyses the synthesis of new DNA strands which are direct 
replicas of the target sequence.  
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Generation of restriction sites 
Restriction sites can be used in different ways for cloning PCR fragments. The simplest 
way is to employ natural sites within the target DNA (should be in suitable positions). 
Another method involves the use of PCR to change the DNA sequence by introducing a 
new restriction endonuclease site (see diagram below). 
 
In this way it is possible to introduce restriction site sequences into PCR products by 
having these sequences incorporated into the 5' end of the PCR primer(s). The short 
restriction site sequence on the 5' end of the PCR primer will not hybridise, and 
therefore may decrease the specificity of the PCR reaction at the beginning. As long as 
the 3' hybridising region is long enough, the primer will specifically bind to the 
appropriate site. Thus, the PCR product will have an additional DNA sequence at the 5' 
end which will contain the restriction enzyme site. A different restriction site sequence 
can be added via the other PCR primer. For ligation reactions, the PCR fragment can 
be inserted in a directional dependent manner in a host plasmid. 
 
The following primers, containing the restriction sites for subcloning, were used to 
amplify homologous sequences for the targeting vector: 
(1) XbaI-for and XbaI-rev (containing exon 1 and interrupted exon 2: size: 1.8 kb) 
(2) ClaI-for and BamHI-rev (containing exon 3 and 4: size 2.4 kb) 
 
and isogenic DNA derived from 129/Ola mice as template DNA. 
 
Reaction: 
PCR was performed in many cases. Important reactions will be illustrated later in the 
methods, where they are integrated. General protocol per 25 µl reaction: 
 
mixture:   - PCR-buffer (10x)     1x (final concentration) 
- dNTPs (5 mM each)    0.8-1 mM (final conc.) 
- Primers (20 mM each)    0.8 µM each (final conc.) 
- Taq-DNA Polymerase    1-1.5 U 
- genomic DNA       150-300 ng or 
- BAC or plasmid DNA    15-25 ng 
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> for fragments up to 1.5 kb:  
Cycle conditions were 30 sec at 94oC, 30 sec at the appropriate annealing temperature, 
and 1-2 min (regarding to the size) at 72oC for 30-35 cycles. PCR negative controls 
were performed by replacing the template DNA with H2Odd. The MgCl2 concentration 
was between 1.5-1.75 mM. 
 
> for fragments between 1.5 and 5 kb:  
Cycle conditions were 30 sec at 94oC, 30 sec at the appropriate annealing temperature, 
and 2-3 min at 72oC for 10 cycles. The next 20-25 cycles contained additional 20 sec 
per cycle (e.g. n=11: 2`20”, n=12: 2`40” etc) at 72oC. The MgCl2 concentration was 
higher (2-2.25 mM)(negative controls see above). 
 
Long distance PCR (up to 20 kb) 
Primer pairs Tff1f 3’-UTR/Tff2r 5’-flanking and Tff2f 3’-UTR/Tff3r 5’-flanking (Table 4) 
were used for inter-gene PCR amplifications to determine the distances between the 
trefoil genes in mouse using the Expand™ Long Template PCR System (Roche 
Molecular Biochemicals) following manufacturer’s protocol. 
 
 
3.4  Ligation 
 
During the ligation reaction, both the linearised vector and the insert of interest were 
mixed and ligated by the enzyme T4-DNA ligase. The vector was digested with the 
considered restriction enzyme and recovered after gel electrophoresis. The resulting 
fragment was dephosphorylated (if only one enzyme in use) to prevent self-ligation. The 
insert was prepared with the same restriction enzymes and purified by gel 
electrophoresis. 
20-50 ng of the pre-treated vector were used per ligation reaction. The amount of insert 
was calculated individually. For ligation with overhangs, a 3-5 (BAC-DNA shot-gun: up 
to 10) to 1 molar insert to vector ratio was used. The entire ligation mix contained in 
addition to the mentioned components, 10x T4-DNA ligase buffer and 1.5 Weiss-units of 
the enzyme T4-DNA ligase. Ligation happened O/N at 4oC and the linearised vector 
without insert served as negative control. 
 
TA-cloning of PCR products 
Taq and other polymerases seem to have a terminal transferase (“extendase”) activity 
which results in the non-template addition of a single nucleotide to the 3'-ends of PCR 
products (Clark, 1988). In the presence of all 4 dNTPs, dATP is preferentially added 
(Mead et al., 1991). This terminal transferase activity is also the basis for the TA-cloning 
strategy: Taq polymerase is used to add a single dT to the 3'-ends of a blunt-cut cloning 
vector such as pGEM-T (Promega; Fig. 8A), and simple ligation of the PCR product into 
the "sticky-ended" plasmid. 
This method was used to clone the primarily “XbaI-sited” PCR fragment and the 
“ClaI/BamHI- sited” PCR fragment of the mouse Tff2 gene. 
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Verification of the clones 
The insert or the sequence of interest was determined by restriction analysis and 
sequencing using the dideoxy chain termination method (refer to 3.13). 
 
BAC-DNA shot-gun cloning 
This method is used to subclone large BAC inserts to select the fragments of interest. 
For that reason 5 µg of BAC DNA (here: 123M10) was digested with 10 Units of 
PstI+XhoI and XbaI+XhoI, respectively, with the appropriate buffer. After the 
electrophoresis (restriction check) the purified BAC DNA fragments were ligated with 
the pBK-CMV vector (Fig. 8B), which was prepared with the same restriction enzymes 
and purified by gel electrophoresis. For further preparation see 3.11 (colony 
hybridisation). After identifying of the desired fragments, they were transferred into the 
polylinker sites of pL2-neo (Fig. 8C) by an additional cloning step  to complete the 
targeting construct. 
 
 
3.5  Screening BAC library 
 
BAC recombinants harbouring genomic mouse DNA from strain 129/Sv were obtained 
from Research Genetics, Huntsville, AL, USA. Oligonucleotides (Table 4) were 
designed from cDNA or genomic sequences (GenBank database accession No. 
Z21858, U78770, AJ 271002-271004; Chinery et al., 1996b) to screen recombinants by 
PCR. These PCR products were also used as 32P labelled probes to verify and 
characterise the recombinants by Southern blotting and hybridisation as described 
(Church and Gilbert, 1984). 
 
PCR 
Thirty cycles of PCR amplification were undertaken at 95oC for 30 sec and at the 
appropriate annealing temperature for 30 sec, as well as 72oC for 3 min. The purified 
PCR amplification products of 884 bp for Tff1, of 928 bp for Tff2 and of 1190 bp for Tff3 
were then labelled with the random primed reaction (refer to 3.7). 
 
BAC DNA Isolation 
From an O/N culture of the BAC clones 0.5 ml was inoculated into 100 ml of LB medium 
with 12.5 µg/ml chloramphenicol and cultured at 37°C with vigorous shaking (∼250 rpm) 
for 16 h.  
For BAC DNA purification, the Qiagen Plasmid Midi Kit was used (alkaline lysis, 
(Birnboim and Doly, 1979) and the manual provided by manufacturer was followed. 
Quantity and quality of DNA are dependent on the BAC clone itself such as insert size 
etc.. DNA quality and quantity were tested by digesting it with restriction enzymes and 
running a 1% agarose gel for 1 h. 
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Figure 8: Vector maps of the T/A vector pGEM-T (A), the pBK-CMV vector (B), and pL2-neo vector used 
for the targeting construct (C). 
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3.6  Transformation 
 
Electroporation 
The preparation of cells for electroporation is easier than preparing chemical competent 
cells. Bacteria are grown to mid-log phase, chilled, centrifuged, and then washed three 
times with autoclaved H2Odd to reduce the ionic strength of the cell suspension. The 
bacteria (SURE strain, XL1-Blue MRF´strain) for electroporation (Dower et al., 1988; 
Taketo, 1988) were prepared according to the protocol of “Current Protocols in 
Molecular Biology” detailed in `section 1.8` (Introduction of Plasmid DNA into Cells) 
(Ausubel et al., 1995). One cell aliquot of 50 µl per transformation was used. 
 
Chemical transformation 
For this procedure, which was developed by Hanahan (Hanahan, 1983), the frozen 
competent cells were prepared and transferred according to the laboratory manual 
”Molecular Cloning” (Sambrook et al., 1989) detailed in `section 1.76` using the FSB-
buffer. A cell aliquot of 100 µl was used here. 
 
Guiding principles: 
Keep the cells as cold as possible during the whole procedure and manipulate the cells 
as gently as possible. The final ligation reaction, which combines the PCR or BAC-DNA 
fragments and the vectors (pGEM-T or pBK-CMV or pL2-neo), occurs in a very small 
volume containing ng amounts of vector plus insert product all mixed together. 
Electroporation uses strong, brief pulses of electric current to punch holes in the cell 
membranes of the E. coli. If 1 to 2 µl of the final ligation mix is added to the cells just 
prior to electroporation, a fraction of the cells will absorb some of the DNA through 
these holes.  
 
Preparation and procedure for electroporation: 
 
• Check that the cuvette holder has been placed in the freezer. Also check that the settings on 
the electroporator are set to 1.6 kV and a pulse duration of 5 msec. 
• Fill ice box and place cuvette (1 mm-gap cuvettes are used), ligation mix, and electro-
competent cells in box. 
• Add 5-10 ng of the ligation mix to 50 µl of electro-competent cells and incubate for 5 min. 
• Transfer the mixture of cells and ligation to the cold cuvette with a pipette; mix gently. Cap 
the cuvette and shake it down once to be sure that the cells are evenly along the bottom of 
the cuvette. Place it into the holder. 
• Push the button for electroporation. The time constant should be close to 5 milliseconds. (If 
the cuvette pops it is bad. Add electro-competent cells to one of your extra cuvettes and try 
again. If it still pops there is probably too much salt). 
• Immediately withdraw the cuvette and add the pre-warmed (37oC) 950 µl SOC to it; mix it 
directly, but gently; and transfer the cell mix into the 12-ml tubes.  
• Leave the cells to recover in the 37°C shaking incubator for 60 min. 
• Plate ~100 µl or a certain volume of the cells on pre-warmed selective LB-plates (with IPTG 
and X-gal, if blue/white selection is possible) 
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3.7  Random oligonucleotide-primed synthesis 
 
Random oligonucleotide-primed synthesis is the method for producing uniformly 
radioactive DNA of high specific activity (Feinberg and Vogelstein, 1983) and for 
carrying out the labelling procedure. The DNA fragment containing the sequence of 
interest is purified by gel electrophoresis. Denature the resulting linear DNA molecules 
by boiling, anneal to random-sequence hexanucleotides, and then incubate with the 
Klenow fragment in the presence of dNTP. In this way, the hexanucleotides prime the 
DNA of interest at various positions along the template and are extended to generate 
double-stranded DNA allowing labelling of both strands. 
 
Standard assay: 
   25 ng denatured DNA 
   3 µl  dATP, dGTP, dTTP mixture (0.5 mmol/l) 
   2 µl  reaction mix (containing random hexanucleotide oligos) 
   5 µl  =50 µCi [α32P] dCTP, 3000Ci/mmol 
   1,5 µl Klenow enzyme (2 U/µl) 
   make up to 20 µl with H2Odd 
and incubate for 45 min at 37oC and stop the reaction by adding 2 µl 0.2 M EDTA (pH 
8.0) and/or by heating to 65oC for 10 min. 
 
When using labelled DNA for hybridisation, removal of non-incorporated dNTPs was 
performed by ethanol precipitation. Followed as below: 
 
- add 2 µl tRNA (25 mg/ml) and 1/10 Vol. 3 M NaAc and 2 Vol. cold EtOHabs 
- precipitate for 45 min at –70oC  
- centrifuge for 15 min at 13000 rpm, RT 
- remove the fluid phase and wash the pellet with 70 % EtOH 
- centrifuge for 5 min at 13000 rpm, RT 
- remove the EtOH and resuspend in 100 µl 1xTE buffer 
 
Before hybridisation, the probe was heated at 100oC for 10 min and cooled on ice. 
 
 
3.8  Southern Blot 
 
Southern blotting has been one of the milestones of DNA analysis since it was first 
described by E.M. Southern (Southern, 1975). This technique is used to transfer DNA 
from its position in the agarose gel to a nylon membrane placed directly above the gel. 
The DNA is denatured, neutralised, and transferred in a high-salt buffer by capillary 
action through the gel and into the papers above. The denatured DNA in the gel moves 
passively with the buffer and is stopped by the membrane. The denatured, single-
stranded DNA binds to the membrane, is permanently bonded by cross-linking with UV-
light, and is hybridised to a radio-labelled probe to detect hybridising DNA samples. 
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UV-crosslinking is recommended for a nylon membrane as this leads to covalent 
attachment and enables the membrane to be reprobed several times. The membrane 
must be completely dry before UV-crosslinking. 
 
Procedure: 
- Photograph gel with ruler 
- Depurinate gel 15 min RT in 0.25 M HCl 
- Denature gel 15 min RT in 0.5 M NaOH 
- While denaturing, cut nylon membrane to fit gel, cut 3MM (Whatman-) paper (3-4  
         sheets) to size of the gel, prepare appropriate size paper towels for blotting. 
- Set up blot: 
- two layers of 3MM paper as wicks into the transfer buffer 
- gel on top of wicks, remove any bubbles, pre-wetted membrane on top of gel 
- 3MM paper on top of membrane 
- paper towels on top of 3MM paper 
- 250 g weight on top of paper towels 
- 6-18 h to blot (size dependent) 
- Neutralise: 3-5 min , RT, shaking with the 50 mM phosphate buffer 
- Air dry membrane, UV-crosslinking 
- Ready for the hybridisation experiments 
 
Southern blot  was used for different experiments. Generally, 10-15 µg DNA was 
digested with appropriate restriction enzymes, if genomic DNA was investigated, and 5 
µg in the case of BAC recombinants. 
 
 
3.9  Spot hybridisation 
 
In comparison with Southern blot anaylsis, this method provides a more rapid and less 
time-consuming determination of the presence of specific DNA in samples (i.e. clones). 
First, a direct transfer of denatured DNA to "spots" or "dots" on filters or nylon 
membranes is made and the spotted membrane is then hybridised with a labelled 
probe. The dot blots should be prepared on nylon membrane or filter from the batch that 
was used for Southern transfers. 
 
Reagents: 
2M NaOH, nylon membrane, positive control DNA, radio-labelled probe (mainly 928 bp-
fragment of 5’-flanking region of Tff2), solutions are needed for hybridisation. 
 
Procedure: 
- Add 2 µl 2M NaOH to 1 µl (0.5-1 µg) DNA sample, leave it for 10 min at RT (denaturing 
phase) 
- Cut nylon membrane and make marks as usual 
- Spot the DNA solution onto the membrane marked with circular shapes  
- When the solution is spotted down, let the spots air dry, rinse the membrane in 
phosphate buffer and then cross-link the DNA to the membrane 
- The filters are ready for the hybridisation process 
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3.10  Hybridisation 
 
All hybridisation methods depend upon the ability of denatured DNA to re-anneal when 
complementary strands are present in an environment near but below their Tm. In a 
hybridisation reaction with double stranded DNA on a nylon membrane and a single-
stranded DNA probe, three different annealing reactions occur. First, there are the 
desired probe-template DNA interactions which result in a signal. Second, there are 
mismatch interactions that take place between related but non-homologous sequences. 
These mismatch hybrids are the ones that will be eliminated during the washing of the 
membranes. Non sequence-specific interactions also occur as background noise 
signals. The ability to extract information from a particular hybridisation experiment is a 
function of signal-to-noise ratio.  
 
Procedure: 
To prevent the non-specific binding pre-hybridisation of the nylon membrane should be carried 
out at 65oC for a few hrs. Add labelled probe to 20 ml Hyb-mix and hybridise O/N at 65oC in the 
hybridisation oven. Hybridisations are performed in the Hyb-mix buffer. 
 
High stringency conditions are necessary for washing the blots: 
-2 times for 5 min in Wash solution I at RT  
-2 times for 15 min in Wash solution II at 65oC 
-2 times for 5 min in Wash solution III at 65oC (optional) 
 
The membranes must be exposed for autoradiography at –70oC with an intensifying 
screen and developed after 1-5 days (depending on the experiments). Or radioactivity 
on the membranes is visualised by phosphor imaging on Personal Molecular Imager FX 
(refer to 3.16). Quantity One analysis software should be used to quantify bands on 
images generated with the Imager System. 
 
Stripping probes from blots: 
-incubate in the hybridisation oven at 80oC for a few hrs in 20 ml of Wash solution II 
-rinse blot thoroughly in distilled water tap. 
 
 
3.11  Colony hybridisation 
 
BAC-DNA shot-gun cloning  
The detection of desired fragments out of complex genomes requires shotgun cloning 
(or subcloning) of BACs into vectors that carry smaller inserts and that can serve as 
templates for generating targeting vectors. 
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By using the colony hybridisation method (Grunstein and Hogness, 1975), a very large 
number of colonies of E. coli carrying different plasmids can be rapidly screened to 
determine which plasmid contains the specific DNA fragment. The colonies to be 
screened are formed on nitrocellulose filters or nylon membranes. After a reference set 
of these colonies is prepared by replica plating, the cells are lysed and their DNA is 
denatured and fixed to the filter in situ. The resulting DNA-prints of the colonies are then 
hybridised to a radioactive probe that defines the sequence of interest, and the result of 
this hybridisation is assayed by autoradiography. Colonies whose DNA-prints exhibit 
hybridisation can then be picked from the reference plate. 
 
This method is employed to isolate and characterise, respectively, clones of the BAC 
123M10 shot-gun plasmids that contain the desired 5‘-part sequences (PstI-XhoI 
fragment or XbaI-XhoI fragment) of Tff2. For screening/hybridisation of the clones, 
including the 5’lanking DNA of Tff2, the 928 bp probe (5’-DNA and exon 1 of Tff2) is 
used. 
Probe preparation: The DNA is labelled by random primed method (refer to 3.7) with 
[α32P] dCTP (3000 Ci/mmol). 
 
Material & Method: 
• Butterfly membrane for colony lifts (with write-on tabs and orientation notches) 
• Prepare the solutions as follows: 
solution 1:  1.5 M NaCl, 0.5 M NaOH, 0.1 % SDS (denaturing & lysis) 
solution 2:  1 M Tris-HCl, pH 7.4 (neutralisation) 
solution 3:  1.5 M NaCl, 0.5 M Tris-HCl, pH 7.4 (neutralisation) 
• Cut three pieces of Whatman 3MM filter paper to the appropriate size and fit them into the 
bottoms of three glass trays. 
• Saturate the pieces of 3MM filter paper in each of the solutions prepared before. 
• Place the (82 mm disc) membrane on the surface of the agar plate until completely wet 
(don’t forget to mark the orientation). 
• Afterwards the membrane is placed colony side up on filter paper saturated with solution 1 
for 7 min. 
• Transfer the membrane to 3MM filter paper saturated with solution 2 for 5 min, then place on 
filter paper saturated with solution 3 for 5 min. 
• Place the membranes, colony side up, on a dry sheet of 3MM filter paper. Allow the filters to 
dry for a minimum of 30 min at RT. 
• DNA was fixed to the membranes by UV irradiation with a Stratalinker™ (120 mJoules/cm2 
at 254 nm for 3-5 mm diameter colonies). 
 
 
3.12  DNA extraction 
 
Ethanol Precipitation 
Procedure: 
• Measure the volume of DNA containing sample. If the volume is less than 450 µl, place it in 
a 1.5 ml eppendorf tube.  
• Add 0.1 Vol. of 3M NaAc pH 5.2 (mix) and afterwards 2 Vol. of cold EtOHabs; mix. 
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• Place the sample at –20oC (if there is a lot of DNA, you can proceed almost immediately. If 
there is only a few hundred ng, it is best to wait at least one hour or O/N) or at –70oC for 1 
hr.  
• Centrifuge at 14000 rpm, 4oC for 20 min 
• Decant the supernatant, and tap the tube (upside down) on a paper towel to remove as 
much EtOH as possible. Keep the tube upside down (take care: you may loose the pellet, if 
detached) 
• Wash it with 70 % EtOH, centrifuge (see above) 
• Remove the EtOH again, dry in Speed-Vac for 5 min 
• Resuspend in an appropriate volume of TE buffer or H2Odd  
 
 
Isolation of plasmid-DNA 
 
 Mini-prep 
Bacterial cells are lysed in NaOH/SDS to denature proteins and chromosomal DNA 
(Birnboim and Doly, 1979). 
 
Procedure: 
• Grow 3 ml over night (O/N) culture with appropriate antibiotics 
• 1.5 ml into microfuge tube, centrifuge 1 min max. speed. Keep pellet 
• Add 250 µl of E1 solution, vortex briefly 
• After pellet is in solution, add 250 µl of E2 solution, mix by inverting, RT 5 min  
• Add 250 µl ice cold of E3 solution, mix by inverting, and for 10 min on ice 
• Centrifuge (14000 rpm), 20 min at 4oC 
• Transfer supernatant to new tube, add 0.7 Vol. isopropanol, vortex 
• Centrifuge (14000 rpm), 20 min at 4oC 
• Remove all isopropanol and keep visible DNA pellet 
• Wash: add 150 µl of 70% EtOH 
• Centrifuge (14000 rpm), 20 min at 4oC 
• Dry down 
• Resuspend in 30 µl TE pH 8.0 or H2Odd 
 
 Midi-prep 
This procedure is the method of choice for isolating large amount of double stranded 
plasmid-based templates for restriction or sequence analysis. It employs a modified 
alkaline/SDS method to prepare the cleared lysate. After neutralisation, the lysate is 
applied onto a column and the plasmid DNA is bound to the anion exchange resin. 
Washing the resin removes RNA and all other impurities. Afterwards, the purified 
plasmid DNA is eluted from the column and finally concentrated by an alcohol 
precipitation.  
For this purpose, the Jetstar Plasmid Purification System was used and following the 
manual provided by manufacturer (Genomed, D). 
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3.13  Sequencing analysis 
 
Two main sequencing techniques are in common use: the chemical degradation method 
of (Maxam and Gilbert, 1977) and the enzymatic (dideoxy chain termination) method 
(Sanger et al., 1974). 
The enzymatic method is by far the most popular and widely used technique for DNA 
sequence determination. Thermal cycle sequencing is a method of dideoxy sequencing 
in which template DNA is amplified in linear fashion using a single primer and 
thermostable DNA polymerase. This technique has several advantages as compared 
with conventional dideoxy sequencing. Since the primer extension reaction is performed 
not just once but 20-35 times, a smaller amount of template DNA is required (Krishnan 
et al., 1991). 
 
Various plasmid DNAs were sequenced using different primers (Table 4), generally 
starting approximately 30-50 bp away from the sequence of interest. The reaction was 
prepared as following: 
 
   1 µg    plasmid-DNA or 
   0.3-0.5 µg  BAC-DNA 
mix: 
   0.5 µl   Primer (10 pmol/µl) 
   4.0 µl   Sequence-mix 
make up to 20 µl with H2Odd 
 
 
Cycle sequencing: 
Program:    96oC  10 sec 
       50oC  5 sec 
       60oC  4 min  
        cycle: n=25 
       4oC   ∞ 
 
Samples were run under denaturing conditions in the presence of 1x TBE. 
Running conditions: pre-run: 2500 V, 50 mA, 40 W for 30 min at 51oC 
main-run: 2500 V, 50 mA, 40 W for 8 h at 51oC  
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3.14  Gene targeting 
 
3.14.1 Construction of a replacement vector  
 
Figure 9: Two strategies to create a replacement construct. The arrows indicate the point to linearise. 
 
 
The targeting vector is designed to recombine with and mutate a specific chromosomal 
locus. The minimal components are sequences (availability of a genomic clone 
containing the gene of interest) which are homologous with the desired chromosomal 
integration site and a plasmid backbone. 
 
In the first method (Fig. 9; I), the target gene fragment is subcloned into a plasmid 
vector; the neo is inserted into a rare restriction enzyme site in the target gene 
fragment. In method II, which was used for this work, the target gene fragment was 
cleaved into two pieces that were subcloned into the polylinker sites of pL2-neo (Fig. 9). 
Note that the relative orientation of homologous fragments in the construct must retain 
the one found in the target gene. 
 
The following are guidelines for the construction which generates an easily identifiable 
null allele: 
* use a fragment of isogenic homologous sequences of 5-8 kb (here: 5.45 kb) 
* insert the neor gene into an upstream exon or important 5’ exons 
* interrupt or delete exons without a unit number of codons to avoid generating a  
  protein product with partial or novel function after RNA splicing 
* for PCR: clone the selection marker so that one arm of homology is 0.5-2 kb  
* linearise the vector outside the homologous sequences  
* design a diagnostic Southern screening strategy (here: BamHI and XbaI) 
 
Figure 10 describes procedures involved in gene-targeting and the generating of 
knockout mice (an overview). 
  Methods 
     52
 
Figure 10 : Overview; procedures involved in the generating of knockout mice. 
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3.14.2 Detect gene targeting events in ES cells 
 
Embryonic stem cells 
The embryonic stem (ES) cells initially used were derived from 129/Ola mice and are 
commonly called GK129 cells. A second ES cell line, called AB2.2, was also employed, 
derived from 129/Sv mice (new nomenclature: 129/S1; Simpson et al., 1997). AB2.2 
cells are commercially available from Lexicon Genetics, TX, USA. 
 
Positive Selection 
The neor cassette, placed internally into the targeting vector, serves as a marker for 
positive selection as well as a potential inactivator of the targeted gene (DeChiara et al., 
1990). The construct, which had been transfected into ES cells in culture, positively 
selected cells, were further analysed. The neor gene, encoding a bacterial 
aminoglycoside phosphotransferase, renders a given cell resistant to the antibiotic 
G418 (Colbere-Garapin et al., 1981). To isolate cells carrying a targeted mutation, all 
the cells are cultivated in a G418 media (200-275 µg/ml G418 for 250 ml ES media). 
 
Picking and Expansion of Colonies after Electroporation 
After electroporation and selection, the ES cell colonies take 8-12 days of growth to 
become visible with the eye and can be picked at this time. The ES cells clones are 
seeded into 96-well plates and grown for 5 days. Then, one-half of the cells are frozen 
in the original plate while remainders are grown in a replica plate for PCR and Southern 
blot analysis. 
 
 
3.14.3 Detection of homologous recombinants  
 
PCR analysis using DNA prepared directly on the 96-well plates 
For the DNA extraction, the cells are rinsed with PBS and lysed by proteinase K in the 
plate. The rest of the extraction steps are carried out in the same plate, discarding the 
solutions by gentle inversion and leaving the nucleic acids attached to the plate. DNA is 
precipitated by adding 50 µl isopropanol to each well and by allowing the plate to stand 
for 30 min at RT. After centrifugation (1200g, 5 min at RT) empty the wells and wash the 
DNA three times by filling and emptying the wells with 70% EtOH. Finally, allow the 
wells to dry for 20 min at RT and resuspend DNA in 30 µl H2Odd. 
 
Screening for homologous recombinants was first undertaken with pools of ES cell 
clones. The screening method of choice was PCR (very sensitive and rapid). It could 
also have been performed on crude cell lysates (described above). For the detection of 
a gene targeting event, the homologous recombined DNA region was amplified with two 
primers: one specific for the mutation (targeting vector: Reko-for) and the other for the 
endogenous (non-vector) DNA (WT-rev). In this way, a correctly sized PCR product (2.4 
kb) would only be generated if two primer sites were juxtaposed by homologous 
recombination.  
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A PCR screening has the advantage that it can be conducted with minimal expansion of 
ES clones from cells in 96-well plates (Ramirez-Solis et al., 1992). Possible 
recombinant clones are further verified for the correct integration by Southern blot 
analysis. Homologous recombination should lead to the generation of a additional 
restriction fragment, readily distinguishable from a fragment of the endogenous copy. 
Sufficient DNA can be obtained for this analysis from colonies of 12- or 24-well plates. 
 
PCR Taq polymerase was used in the presence of 2.25 mM MgCl2. Cycle conditions 
were 94oC-4 min; 94oC-30 sec, 59oC-30 sec, 72oC-3 min (10 cycles); 94oC-30 sec, 
59oC-30 sec, 72oC-3 min plus an additional 20 sec per cycle (25 cycles); 72oC-7 min. 
Products were analysed on 0.7% agarose gels after ethidium bromide staining. To 
detect the homologous recombined events the primer pair Reko-for/WT-rev (expected 
size: 2.4 kb) was used. By using WT-for/WT-rev (~2.65 kb) primers the quality of DNA 
was tested, as well as a control. 
 
For Southern blots, 15 µg of digested (I: BamHI and II: XbaI) ES cell DNA was 
subjected to agarose (0.7%) gel electrophoresis and transferred to nylon membranes. 
Probes were labelled by random priming using [α32P] dCTP. The 928 bp fragment (Fig. 
24) of the Tff2 gene was used as a probe. 
 
 
3.14.4 ES cell injection 
 
Clones identified as positives were thawed, expanded, and micro-injected into 
C57BL6/J day 4 embryos (blastocysts). The colleagues at the transgenic lab routinely 
inject 36 blastocysts per clone and usually inject two positive clones per project. 
Injected blastocysts were transferred into day 3 pseudo-pregnant female mice (CBAx 
C57BL6/J females for pseudo-pregnants were used). 
 
 
3.14.5 Chimeras 
 
The generation of chimeras between ES cell clones and embryos is an essential step in 
these processes which, when successful, leads to the derivation of new strains of mice 
with the desired altered genome. Approximately 18-21 days after transfer pups will be 
born; about 7-10 days after birth they can be phenotyped for coat colour contribution 
and sexed. 
The evaluation of chimeric animals is necessarily subjective, but in general, the degree 
of coat colour chimerism of a particular animal correlates with the degree of germline 
contribution. To determine whether a chimera shows germline transmission, the 129/Sv-
C57BL6/J chimeras are backcrossed with C57BL6/J mice (breeding of heterozygous 
strains). 
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3.14.6 Mouse tail biopsies  
 
Germline transmission was determined by DNA typing (Southern blot analysis) of tail 
biopsies. 
 
DNA extraction: 
• Remove 0.5 cm of tail into polypropylene microfuge tube (do not mince). 
• Add 0.5 ml digestion buffer with 25 µl of a 10 mg/ml proteinase K  
 
 digestion buffer:  50 mM  Tris-HCl  
         (pH 8.0)     100 mM  EDTA 
100 mM  NaCl 
1 %   SDS 
 
• Incubate overnight at 50-55 °C with gentle shaking. 
• Add 0.7 ml neutralised phenol/chloroform/isoamyl alcohol (25:24:1). 
• Mix fairly vigorously (do not vortex). 
• Spin in microfuge at top speed 10 minutes and transfer the upper phase to new 
microfuge tube. 
• Add 2 Vol. EtOHabs at RT and invert until DNA precipitate forms. 
• Spin in microfuge 10 minutes and carefully remove and discard supernatant. 
• Add 0.5 ml 70% EtOH (-20 °C) and invert several times. 
• Spin in microfuge 10 minutes and carefully remove and discard supernatant. 
• Air dry at room temperature. 
• Add 100 µl TE buffer and incubate at 65°C for 15 minutes to resuspend DNA. 
 
The total yield is approximately 20-50 µg DNA. An amount of 10-15 µg was used for 
restriction enzyme (BamHI) digestion to confirm the germline transfer. 
 
 
3.15  Pulsed-Field Gel Electrophoresis (PFGE) 
 
DNA molecules larger than 25 kb in size must squeeze to get through even the largest 
pores and cannot be sieved by a gel. Molecules in the size range all migrate at about 
the same rate, called “limiting mobility”. 
A solution to this problem was found in 1984 when Schwartz & Cantor reported the 
development of pulsed-field gel electrophoresis (Schwartz and Cantor, 1984). Here, the 
CHEF-PFGE was used (contour-clamped homogeneous electric fields; Chu et al., 
1986). 
Procedure: 
Day 1: setting up the pulsed field gel 
BAC DNA digested by rare cutters like MluI or NotI or SalI was separated with 1 % agarose 
gel in 0.25x TBE using LKB 2015 pulsator electrophoresis unit (Pharmacia).  
Program electrophoresis parameter: a linear pulse time gradient from 5 to 15 sec was 
applied for 20 h at 180 V constant voltage. 
Day 2: staining and documenting the gel and preparing of Southern blot . 
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3.16 Autoradiography 
 
3.16.1 Exposure to X-ray film 
 
Preparing the membrane for autoradiography: 
In a darkroom, place the nylon membrane (wrapped in Saran wrap) in a light-tight 
exposure cassette and cover it with a sheet of X-ray film. Expose the film for an 
appropriate length of time. When intensifying screens are used, the film must be 
exposed at –70oC. The low temperature stabilises the silver atoms and ions that form 
the latent image of the radioactive source. 
 
X-ray film may be developed by hand as follows: 
  Developer:     3-5 min 
  water (stop bath):  1 min 
  Fixer:      5 min 
  Running water:   10 min 
The temperatures of all solution should be 18-20oC. 
 
 
3.16.2 Using storage phosphor and phosphor imaging 
 
In this case the use of photostimulable storage phosphor imaging plates was described 
as an alternative to film for recording and quantifying autoradiographic images 
(Personal Molecular Imager FX from Bio-Rad). The scanner can scan at resolutions of 
50, 100, 200 and 800 microns. The advantages of storage phosphors over film are a 
linear dynamic range covering five orders of magnitude and a sensitivity 10 to 250 times 
that of an X-ray film. 
The imaging plates are composed of fine crystals of BaFBr: Eu+2 in an organic binder 
(Amemiya and Miyahara, 1988). High energy radiation (e.g., X-rays, ultraviolet light, 
gamma rays or beta radiation from a hybridised membrane) will excite an electron of the 
Eu+2 ion into the conduction band. This electron is then trapped in an “F-center“ of the 
BaFBr- complex with a resultant oxidation of Eu+2 to Eu+3. The excited BaFBr- complex 
exhibits a distinct absorption band centred around 600 nm. By exposing the excited 
complex to light from a laser (635 nm), the electrons are liberated back to the 
conduction band reducing Eu+3 to Eu+2*. Eu+2* then releases a photon at 390 nm as it 
returns to ground state (Sonoda et al., 1983). Trapped energy is released as photons 
that are in turn captured by a photomultiplier tube. 
The analysis software (Quantity One, BioRad) permits control of the scanning system 
and accurate analysis of the captured image or data. 
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4. Results 
 
4.1  Construction of the targeting vector for disruption of Tff2 
 
The main aim of this project was not only to establish a targeting vector, that disrupts 
the Tff2 gene by removing a large part of exon 2, but to characterise a successful 
germline transmission of this mutant allele to heterozygous (Tff2+/-) mice. 
The target gene was cleaved into two pieces, a proximal part containing exon 1 with 
small part of exon 2 and the distal part with exon 3 and 4 (strategy I, Fig. 11). 
Afterwards they were subcloned into the vector pL2-neo, containing a neomycin 
cassette flanked by loxP sites for further selection (G418) and interrupting the desired 
gene. It was not intended to use Cre-mediated recombination of loxP to delete the neo-
gene. However, if it were found to affect the expression (Olson et al., 1996; Pham et al., 
1996) of neighbouring Tff genes, the neo gene could be simply removed by crossing the 
Tff2 knockout strain with a Cre-mouse. Figure 11 shows the genomic arrangement of 
the Tff2 gene, which contains four exons (exons 2 and 3 coding for the trefoil motifs), 
and the strategy to develop the Tff2 knockout by removing a sufficient part of exon 2.  
The sequence data was obtained from GenBank (accession No. U78770) and personal 
communication (O. Lefebvre). 
  
 
 
 
Figure 11: Construction strategy of the first targeting vector. (A) The Tff2 gene locus. Ligation of PCR-
products using modified primers with pL2-neo (B) results in targeting construct (C). The horizontal arrows 
indicate primer orientation. Solid black boxes indicate the four exons of Tff2. B, BamHI; X, XhoI; X/X* 
(blue) XbaI; E, EcoRI; H, HindIII; K, KpnI; MCS, multiple cloning site. 
 
  Results 
 59
 
The Tff2 gene was amplified by using the designed primers m2-pro and m2-end (4.9 kb: 
Fig. 12 A). A 2.4 kb genomic DNA fragment (Fig. 12 B) was generated by PCR with the 
use of ClaI-for and BamHI-rev primers, containing corresponding restriction sites. A 
second fragment (1.8 kb) was obtained with the primers XbaI-for and XbaI-rev (Fig. 12 
C). 
 
 
     A           B           C 
 
 
Figure 12: PCR amplification of the Tff2 gene (A), the ClaI-BamHI fragment (B) and XbaI-XbaI product 
using mouse genomic DNA (m) derived from 129 strain (neg.: negative control, kb: molecular marker). 
 
 
 
The ClaI-BamHI (CB) fragment was subcloned into the T/A-cloning site of the pGEM-T 
vector (Promega), generating the plasmid pT1-CB. After restriction with the appropriate 
enzymes (ClaI and BamHI), it had to be subcloned into the ClaI and BamHI sites of the 
pL2-neo vector. Initially, it was not possible to excise this insert. Detailed analysis 
revealed restriction by BamHI but not by the enzyme ClaI (see circular and supercoiled 
form in Fig. 13). 
 
 
 
 
Figure 13: Restriction of the plasmid pT1-CB using ClaI and BamHI enzymes. 
  Results 
 60
 
However, sequencing of the plasmid demonstrated the existence of both restriction sites 
(Fig. 14). 
 
 
    A                 B 
 
 
Figure 14: Sequence of the ligation boundaries of pT1-CB using M13-primers. The location of restriction 
sites for ClaI (A: ATCGAT) and BamHI (B: GGATCC) are shown underlined. 
 
 
The answer to this problem was the dam gene (Dam methylase) of the E.coli host 
strain. It transfers a methyl group from S-adenosylmethionine to the N6 position of the 
adenine residues in the sequence “GATC” and, therefore, restriction enzyme cleavage 
by ClaI (methylation sensitive) is blocked. By using Dam- strains (GM272) to grow the 
pT1-CB shuttle vector, the modification-dependent restriction was avoided (Fig. 15). 
 
 
 
 
 
 
 
 
 
Figure 15: Restriction enzyme cleavage of pT1-CB  
(v-vector; i-insert). 
 
 
After excision and preparation of the insert, the CB-fragment was then cloned into the 
pL2-neo vector, generating the plasmid pL2-CB (size: 7.6 kb). This was confirmed by 
restriction analyses using different enzymes and sequencing (Fig. 16). The sequence 
data revealed the expected sites of ligation and the sizes of the restriction fragments. 
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 A                B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Restriction (A) and sequence (B) analysis of pL2-CB. The clone was digested with BamHI, 
KpnI, XhoI, HindIII and double digested with XhoI+BamHI as well as ClaI+BamHI. The underlined 
sequences belong to the restriction sites of ClaI (ATCGAT) and BamHI (GGATCC). Note that in host XL1-
Blue MRF´ digestion with ClaI is not visible because of dam-methylation. 
 
 
Another difficulty arose during the cloning of the upstream part of the target gene. 
Despite different modifications of the ligation and/or transformation parameters, the 
XbaI-XbaI fragment (1.8 kb) could not be subcloned into the pGEM-T vector (Promega). 
Interestingly, instead of the desired clone, plasmids with changed insert sizes appeared. 
We concluded that this was due to a recombination event triggered by the pyrimidin-rich 
repeat cluster in intron 1 (total array length: ~340 bp; repeat unit: CTTT and CTTC). 
This region probably leads to genetic instability in E.coli. In support of this idea is the 
fact that it was easy to clone a 928 bp-fragment adjacent to the repeat cluster 
containing 5’-flanking DNA, exon 1 and part of intron 1 (Fig. 17). 
 
 
Figure 17: Restriction of different plasmid-DNA by SalI. Lanes 1-3 correspond to the positive control (512 
bp fragment: total size 3.5 kb) supplied by the manufacturer and lanes 4, 6-8 to the vector only (3 kb). 
Lane 5 (x) shows the ligated 928 bp fragment of Tff2 (total size: ~4 kb). 
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To obtain more sequence data from Tff2, two pairs of primers (no. 1: m2-pro&m2-
250rev and no. 2: m2/251-for&m2/1189-rev) were designed to amplify exon 1 or 5’-
flanking DNA, respectively. These primers were then used for PCR screening of a 
129/Sv genomic DNA BAC library. Three BAC recombinants, 123M10 - 517E16 - 
566K2, harbouring genomic mouse DNA were obtained from Research Genetics. 
Oligonucleotides were designed from cDNA or genomic sequences (GenBank 
accession No. Z21858, U78770, AJ 271002-271004; Chinery et al., 1996b) to screen 
the recombinants by PCR (Fig. 18)(for a more detailed investigation and 
characterisation of BACs see 4.2). 
 
 
 
Figure 18: PCR amplification of a 250 bp product from 5’-flanking DNA of Tff2 using different BAC- and 
mouse genomic DNA (neg, negative control). 
 
 
 
The 928 bp PCR product (Fig. 17) was used as a 32P labelled probe to verify and 
characterise the BAC recombinants by Southern blotting and hybridisation (Fig 19). 
BAC123M10 and BAC517E16 were double-digested with different enzymes to locate 
the desired 5’-flanking DNA fragment of the trefoil gene Tff2 to create the revised 
construct as outlined in strategy II, Fig. 24. 
Because more sequence structure data were obtained for the 5’ flanking region of Tff2, 
the new targeting vector would exclude exon 2, intron 1 (containing the repeat cluster) 
and would take advantage of the XhoI-site in exon 1 (Fig. 11). 
Fragments produced through the PstI-XhoI or XbaI-XhoI (Fig. 19) digestion were of 
major interest, since the sizes (3.0 and 5.0 kb) were suitable for achieving a total size of 
homologues sequences of at least 5 kb. 
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Figure 19: Autoradiograph of the Southern blot of two BACs (123M10 and 517E16), double digested with 
restriction enzymes (RE), showing the hybridisation with the 928 bp probe. Arrowheads indicate the 
signal of fragments useful for the targeting vector (X XhoI; H, HindIII; S, SacI; P, PstI; Xb XbaI; A, ApaI). 
 
In a first assay the PstI-XhoI fragment (~3.0 kb) containing the first three codons of 
exon 1 was subcloned by shotgun cloning into the PstI-XhoI sites pBK-CMV 
(Stratagene) vector (Fig. 20). Two plasmids were generated, which were confirmed by 
restriction analysis and spot hybridisation. 
 
  A                  B 
 
 
 
 
 
 
 
 
 
Figure 20: (A) pBK-CMV vectors digested with PstI and XhoI. Lanes 4 and 5 display the desired insert. 
(B) Spot hybridisation: after miniprep extraction, DNA was denatured and blotted onto nylon membranes 
and hybridised with the 928 bp probe (5’-flanking region of Tff2). PCR+ and C+ represent the 928 bp 
product (positive control), V vector (negative control), and B1/B2 two BAC recombinants containing Tff 
genes. 
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The insert was also sequenced, confirming the presence of the exon 1 and its start-
codon (ATG) as well as the PstI boundary at 5’ end (Fig. 21). 
 
 
A                 B 
 
Figure 21: Partial sequence of the insert. (A) XhoI site (underlined); arrowhead indicates the start codon 
ATG. (B) PstI site (underlined) and unpublished sequences of 5’ part of the gene. 
 
 
As a next step, the PstI-XhoI fragment was excised with AatII and XbaI from the pBK-
CMV plasmid and then subcloned into the AatII-XbaI (insertion in a directional 
dependent manner) of pL2-CB, generating the plasmid “pL2-∆m2”, also called the 
targeting vector. This vector was confirmed by sequencing of ligation boundaries (like in 
Fig. 21; the whole sequence see Fig. 23), PCR, spot hybridisation, and restriction 
analysis (Fig. 22). 
 
A                  B 
 
 
 
 
 
C 
 
 
Figure 22: (A) Several plasmid DNA spotted on the 
membrane and hybridised with 928 bp probe of Tff2. 
For further experiments, positive samples (marked 
arrowhead) were used. “+” represents positive controls, “v“ 
vector pL2-CB (negative control). (B) Digestion of three 
positive clones (36/50/57) and v-vector pL2-CB (size: 7.6 kb) 
with B-BamHI (clones display two bands: 5.5/5.1 kb) and H-
HindIII (one band: 10.6 kb) enzymes. (C) PCR amplification of 
the 250 bp product in 5’ region of Tff2 (H2Odd as negative and 
BAC as a positive control). 
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5’(PstI)- 
ctgcagtcctttgtcctggcaaccatagcatggtaatttggggcagctaatttacttgcaaaatggcttg
attctctcaagacctgctttgaaattcagctagattgggcctggggcacctccactcttgggccagttag
cctgttcctgtggtgtgcctctgcgtctgtctgtaacccatccttgggttcctcgtagtctccttcctca
ggcagggtagagtccaccctcttagaaccactacaaaaccgggagtgtccggctgcctcctacctcgggt
tcagagcatgggggagctcggtcctctaagccttatgctgctgcttccacgcatgctcagcccgctgagc
atcccttccttcctcaatatccgatttgtctggccttcaggtcaaggcagtgaaggatttgactaagaac
tcaaggaactcacatttatggtctgcggcttcgttttcttccttctcccacccagctaccctggttctgg
gcctggttcttgtttctctactctgccttctttccctcctctggattcctgtcatttgacagggctttag
agtcccctacaggagagggtggtctggaccgtttttttctgtgtgctccgagaaagactggctagtacct
gaggaattccagtttgcctgaatagataaacaccatctcccccaaggtgtgcagggagactggggtgggg
ctggaggtgggagtggagagaagacatgagaaaaatcacaccacgaagtcacggctggtctgagagcatg
cgcagaagcagcagcgcgaggcttgcacatgcaagccctggaggaggcagcggggtgctcctggtgttgt
agtgggggggtggtgatgtgagccccctggaagtcgggctggaggagaagaggcacagacaaggagagct
gagctgctgtggagtcgagggttaggatttaaggaagcagctgctgtggtagccacagagaaagtgctag
aagcgagagtgtactgaacgggaaagaagcccgtgttttgtccgtggagagttcaggttctgagagagag
agagagagagagagagagagagagagagagagagagagagagagagagagagaaggggaagttcctagag
tccaggagaagatacagaagatacagagcccggcagccatcagtctgcatgtgacctgcctggggttcag
aagccgtttatgcctgtaccaagatttgggccaatgaccttgggactgagtccttgtcatcagagacggg
tcagtggaccccagtgaggcaggtgcaatagacgtggcacagtgcagagtctgtatccacagcacccata
agttttcctataaagtggaaactgtagctgtggggttctcctgagcctctgtgattggcccacagcctgg
tcccacagatatggctgtctattgttgtgcagtacccttgactttatatggaatggggcgggggtgcagt
gctcataatatggatagcctgttcatcaggacacaggcttgtacagggggaagggataatgctcaaagga
aagataaatgtctcttcaggggacaggtggctttggcggaacccctgatggggcaggggaacttgggttg
ggatgtgggccagagaggagggaggaatgaggatgttcaagaaaatgggttcttggcaagtcttatcatc
ttgatggctgtcctagttgactgccccttgctatgataaccaaaaggaacctggatagaaaagcaattat
ttatccaatacatccctatcagtcagtcattgagggaagtcagacaggaccaccaagcaggaacctggag
gcaggaaccaggaggcaggaactgaagcagagaccatggagaaatgctgcttactggcttccccccaccc
accccccatggcttactcagtctgctttccatctcttgccagatgaccctggcttgtgtcaagttgacac
caaaacagcacagcaacaacaacaacaaagatacgtaataaacacagagataaagaaccgctgggatgtg
ccacagagaaatagagccctgctgggtttgcaaggatccaggtgaggttttgaggatttaggtctgctct
ttagagcctgggatggggccaaggcttttaaattctgtatccgagtcatggactctgtagcctatctccc
acagctgggcagactccttcagccccaaaggacacacacacacacacacacacagtccctctccttctct
cctctgacatttctgttctgagttgtcctgatcccctgggttctgtcctcggtgtccattttacaaatcc
cctctccggggcatttcatgggtgggcatctcagtcctaggcactgtgtgagggaagtgaagtatcccca
cggggcaaagagtgtccagcttcagggatgaagaaagctgcctgccccatgacggctcccttaggccctg
gcggctggtctctgtgtacaacagtccttggggctggcagggagccaggtgaagtagggtgtgccttgca
tcaggaatgcagactgggtcccctggagatgctccccctcccctgggaggctcctggatgtaatgacctt
ctctctctgtgctctttgtttctccatagcgtcattcacttcaaatatttaaaaaacaaaacaaaacaaa
caaacaagaaacaaaaaaagaaaacaaacaaaaaacaaaacctaagaagtctctacagtaggcacaaacc
ttacccagagtaacaccacgaggctaatcccttcctgggtgtgaccctgtgggtgccctattccagttgc
atacgtggcccattcccctttcagtaacctggcacgacccagcctgacccagcccatgtccggaggggtt
tttcccacctcctctgggcctccacttggagccatgtcagcttttctgcacaaagaacctaggaggcttg
gggccacgagtaagggacagttatcagggccattgagcaaacaaacaggagccaataaaatgccagctgg
tgggaactgggcattctgtaggctgcccaggtccagtggagcagacATGCGACCTCGAG-3’(XhoI)
 
Figure 23: Sequence of the PstI-XhoI fragment (3069 bp) used for the targeting construct. Underlined 
sequence data was known at the beginning of work; bold sequence was published in GenBank later by 
Ribieras et al. 2000 (accession No. AJ271003); and important parts (e.g. restriction sites) were confirmed 
by my data (except for red nucleotide). Blue coloured sequence containing PstI site (bold/underlined) is 
unpublished. At the end of the sequence, CDS (coding sequence, yellow) with start codon ATG (bold) 
and XhoI site (bold/underlined). 
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The targeting vector pL2-∆m2 was linearised with AatII and sent to the colleagues at 
ICRF (Transgenic Lab, Clare Hall, UK), where the subsequent step of the work, the 
transfection into ES cells was undertaken. 
 
Figure 24 summarises the revised strategy II to construct a targeting (“knockout”) vector 
by using BAC recombinants as an additional source. 
 
 
  
 
Figure 24: Construction of the targeting vector pL2-∆m2. Mutational inactivation of the Tff2 gene by 
homologous recombination. Top: restriction map of Tff2; middle: 3 kb PstI-XhoI and 2.4 kb ClaI-BamHI 
fragments subcloned into pL2-neo vector. Solid black boxes indicate the four exons of Tff2. The dashed 
lines mark the targeted region for homologous recombination. Bottom: restriction map after 
recombination; a diagnostic BamHI site generates a 6.0 kb fragment using the probe (black&white box) 
indicated, in contrast to a 5.0 kb fragment in the wild-type (WT) mouse locus. A, AatII; B, BamHI; C, ClaI; 
E, EcoRI; H, HindIII; K, KpnI; X, XhoI and Xb, XbaI. 
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In order to further improve the final recombination event by increasing the size of 
homologous sequences, a second targeting vector, namely pL2-∆Tff2 (Fig. 25), with an 
enlarged 5’-flanking DNA (5 kb XbaI-XhoI fragment; Fig. 19) was constructed.  
Shotgun cloning of XbaI-XhoI BAC fragments led to successful generation of pBK-CMV 
plasmids containing the desired 5’-flanking DNA fragment of Tff2. Several hundred 
colonies were investigated by colony hybridisation (data not shown). The insert was 
amplified by PCR using modified primers (additional XbaI site to the XhoI site) to take 
advantage of the XbaI site of pL2-CB and to accomplish the last cloning step. After the 
XbaI restriction of the amplified product, it was subcloned into the XbaI site of the pL2-
CB vector, generating the gene targeting construct pL2-∆Tff2 (Fig. 25). 
 
 
Figure 25: Targeting vector pL2-∆Tff2. For letter description see Fig. 23. 
 
The reactions were confirmed as previously described by spot hybridisation, restriction 
analysis and PCR (Fig 26). The orientation of the insert was determined by PCR using 
the primers m2pro and neo-rev (Fig. 26C) and restriction analysis (fingerprinting-data 
not shown). 
 
 
   A                       B 
 
       C 
Figure 26:  
(A) After the miniprep, the candidates were restricted 
with XbaI (*18 and *21 shows the 5 kb fragment). The 
correctness of the insert was proved by spot 
hybridisation (B); TC1 represents the pL2-∆m2 vector 
(as a positive control). (C) To clarify the orientation 
only contrary primers can produce a 1.2 kb fragment. 
Only clone *21 was correctly orientated. (TC1 as a 
positive control, the vector pL2-CB and H2Odd (neg.) 
are negative controls)  
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4.2 Genomic structure of the Tff gene cluster  
 
4.2.1  Characterisation of the YAC/ BAC contig  
 
By using Tff2 (for BAC) and Tff3 (for YAC) specific oligonucleotides for the BAC and 
YAC murine genomic libraries, the screening yielded one positive YAC and three BAC 
candidates which appeared useful for more detailed studies. PCR with primers 
representing all three Tff (see Table 4) genes disclosed that the YAC contained Tff2 and 
Tff3 sequences, but no Tff1. (Fig. 27). 
 
 
 
 
 
 
 
Figure 27: PCR amplification of YAC-DNA using Tff-primers. Tff3 
primer (P3) produces a 1,14 kb fragment (arrowhead); two Tff2-
primers generate the 250 bp (P2) and 928 bp (P2*) fragment, 
respectively. Tff1 (P1) was negative, expected size ~850 bp (neg., 
negative control) 
 
 
 
All BACs showed products using the 5’-flanking DNA primers representing all three Tff. 
Southern blot analysis displayed, however, that two BACs (517E16 and 566K2) were 
carrying complete Tff1 and Tff2 sequences and only a part of exon 1 of the Tff3 gene, 
while BAC 123M10 harboured all three Tff genes (Fig. 28 and 29).  
 
 
Figure 28: Autoradiograph of the Southern blot of all three BACs showing the hybridisation signals with 
the 884 bp probe of Tff1. All BACs demonstrate the same pattern. (B, BamHI; E, EcoRI; H, HindIII; P, 
PstI; X, XbaI and N, NotI). When using the 928 bp probe of Tff2, again all BACs revealed the same 
pattern (data not shown). 
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Figure 29: Autoradiograph of the Southern blot  of all three BACs showing the hybridisation signals with 
the 1140 bp probe of Tff3. Here two BACs (517E16 and 566K2) present the same pattern. BAC 123M10 
in particular displays signals of longer fragments. B, BamHI; E, EcoRI; H, HindIII; P, PstI; X, XbaI and N, 
NotI. 
 
 
Fingerprinting and PFGE of the BACs by restriction enzymes in analogy to the study of 
the human TFF contig (Gött et al., 1996) resulted in the construction of the mouse 
contig (Fig. 30). The presence or absence of particular Tff genes within the 
recombinants allowed us to place the murine Tff cluster within a genomic fragment 
range of approximately 48 kb. 
 
 
 
 
 
Figure 30: Organisation of the gene cluster of trefoil peptides (Tff) within a BAC/YAC contig. Presence of 
Tff genes were analysed by PCR (+) and hybridisation (x). y indicates hybridisation of smaller restriction 
fragments, suggesting an insert boundary in BAC 517E16 and BAC 566K2. 
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4.2.2  Mapping of the Tff cluster to mouse chromosome 17 
 
Tff3 was previously mapped to mouse chromosome 17 (Burmeister and Meyer, 1997; 
Chinery et al., 1996b) around 17.0 cM next to the genetic markers cystathione beta 
synthase (Cbs) and alpha A crystallin (Crya1)(Hamvas et al., 1996). Therefore, FISH 
analysis was performed using BAC 123M10 and signals were obtained at 17q (Fig 31).  
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Fluorescence in situ hybridisation of the BAC 
123M10 probe showing hybridisation to mouse 
chromosome 17 (17q). 
 
 
4.2.3  Distances and orientation of Tff genes by long distance PCR display the 
murine Tff gene cluster within 40 kb 
 
The three mouse genes of the trefoil factor family were mapped in detail within the 
contig (see Fig. 30) after employing PCR by using appropriate primers. By applying 
oligonucleotide primers chosen from the 5'-flanking and 3'-flanking region of each gene 
(Tff1f 3’-UTR/Tff2r 5’-flanking and Tff2f 3’-UTR/Tff3r 5’-flanking: see Table 4) to long 
range PCR experiments, the distance between the three Tff genes was assessed. Since 
outward-directed primers from known flanking regions or 3'-UTR were chosen, the data 
also disclosed the transcriptional orientation of all three genes. 
 
While a PCR band of 17 kb represents a 18 kb distance between third exon of Tff1 and 
the first exon of Tff2, a PCR product of 9.5 kb indicated a intergenic length of 11.5 kb 
between Tff2 and Tff3 (Fig. 32 and 33). 
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Figure 32: Intergenic distances of the Tff genes shown by PCR 
amplification with appropriate primer pairs.  
Lane 1: the distance between Tff1 and Tff2; lane 2: distance 
between Tff2 and Tff3 (M1, λ-HindII-marker; M2, kb-ladder)(sizes 
calculated by Bio1D-Software, LTF, D). 
 
 
 
 
 
 
 
 
Figure 33: Genomic organisation of the mouse trefoil gene locus harbouring the genes Tff1, Tff2, and 
Tff3 (E: exon). 
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The genomic structures exhibited a similar organisation in man and mouse. For 
example, the gene size of Tff1 is equivalent to human TFF1. The clustered 
chromosomal location strongly suggests that these genes were created by a process of 
gene duplication and unequal crossing over. To confirm this hypothesis, I compared the 
amino acid sequences of the TFF domains, encoded by the central exons that are 
responsible for the modular character of the corresponding genes (Table 6). 
 
Interestingly, the murine Tff2 domains I and II (encoded by two separate exons), display 
more homology to the corresponding human TFF2 domains I and II (red: 83.7 % and 
86.1%) than the domains I and II within each species (41.8 % and 44.2 %). 
 
 
 
Table 6: Sequence relationships between amino acid sequences of TFF domains from Homo sapiens 
(TFFs) and Mus musculus (Tffs). Percent amino acid identities are shown for all pairwise combinations. 
 
 
 TFF1 TFF2-I TFF2-II TFF3 Tff1 Tff2-I Tff2-II Tff3 
TFF1 100        
TFF2-I 58.1 100       
TFF2-II 44.1 44.2 100      
TFF3 53.5 51.1 48.8 100     
Tff1 72.1 60.5 39.8 46.5 100    
Tff2-I 58.1 83.7 44.1 46.5 60.5 100   
Tff2-II 41.8 41.8 86.1 44.1 41.8 46.5 100  
Tff3 51.1 53.5 46.5 76.7 48.8 53.5 48.8 100 
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4.3 Screening of ES cells for homologous recombinant clones by PCR and 
Southern blot analysis 
 
A reliable screening strategy is an essential component of targeting and should be 
developed during construct design. Consecutive screening was applied: a first 
screening (which involved PCR) for the rapid detection of candidate targeted colonies 
(several hundred), and a second one to verify correct targeting by Southern blot 
analysis. A PCR screening ideally employs a primer (WT-rev) adjacent to the region of 
homology (outside the shorter arm, namely the 2.4 kb fragment) and a second specific 
for the novel sequence within the vector sequences (for example the linker of the 
selectable marker; Reko-for). In this way, a correctly sized PCR product is only 
generated when the two primer sites are juxtaposed by homologous recombination (Fig. 
34). 
 
After electroporation and positive selection (G418, to select for neo), ES cell clones 
need to be screened for incorporation of the targeting construct into the correct genomic 
locus. The screening strategy was designed in such a way that a band normally seen on 
a PCR amplification or following Southern blot would be replaced by a band of a 
predicted size if and only if homologous recombination occurred. Since ES cells are 
diploid, only one allele is usually altered by the recombination event. If the desired 
targeting has occurred, this would be detected by two bands representing both, the wild-
type and the homologous recombinant alleles. 
 
Figure 34: Sites of the primer used for the PCR screening (top) and testing (bottom). Only homologous 
recombinant clones will generate the genomic DNA fragment (for description see Fig. 24). Arrows indicate 
the site of primer annealing and solid black boxes the exons. 
 
The ES cell clones were seeded into 96-well plates. One-half of the cells were frozen in 
the original plate, while the remainder were grown in a replica plate for PCR and 
Southern blot analysis. 
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The GK129 embryonic stem (ES) cells initially used derived from 129/Ola mice. In this 
first assay, DNA of eight 96-well plates were investigated (total: 768). In order to review 
practicability and DNA quality, the wild-type allele was tested using the primers 
Tff2ex2for and WT-rev (size: 2.65 kb). This PCR testing worked well, but the screening 
for homologous recombinants yielded no positive clones in these panels. 
 
Subsequently, we changed our strategy and used AB2.2 ES cells derived from 129/Sv 
mice, since the cloned PstI-XhoI fragment part derived from a 129/Sv mouse genomic 
BAC library. 
 
DNA was isolated from 552 ES cell clones and first analysed by PCR. This analysis 
identified one clone that had a correctly sized PCR product (size: 2.4 kb). The intensity 
of the fragment, however, in comparison with the corresponding wild-type allele was not 
equal (Fig. 35, c-B1). It was assumed, that a contamination with another ES cell 
clone(s) was responsible for this result. Additional subcloning of this clone (c-B1) 
generated clones #A1, #E1, and #G9 with an equal distribution of bands corresponding 
to the wild-type and recombinant allele (Fig. 35). 
 
 
 
Figure 35: PCR amplification of correctly targeted ES cell clones (#A1, #G9, and c-B1; blue R) in 
comparison to the wild-type (green W) fragment (as a control). ES cell clone 12-A1 shows no homologous 
recombination. As expected, BAC contains just the wild-type fragment and water is used as a negative 
template control. ES cell clone c-B1 reveals an unequal band intensity. R represents recombinant. 
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Verification through Southern blotting requires that the colonies be expanded in vitro to 
provide a sufficient amount of DNA to carry out the necessary analysis. 
This disruption by homologous recombination was confirmed through Southern blot 
analysis by using the “diagnostic” BamHI site shown in Fig. 24 and an additional site, 
namely XbaI. Previous studies of the restriction map of Tff2 displayed a XbaI fragment 
above 12 kb using the 928 bp Tff2 probe. Homologous recombinant clones would 
indicate a “diagnostic” 5 kb hybridisation signal, due to the XbaI site in the polylinker of 
targeting vector pL2-∆m2. Indeed, this could be demonstrated in subclones #A1, #E1 
and #G9 (Fig. 36). 
 
The additional DNA band of approximately 9 kb is unspecific since it also appears in the 
wild-type mouse. 
These results were verified by BamHI restriction, resulting in bands corresponding to 
the expected sizes of wild-type and recombinant alleles. 
 
 
 
 
 
Figure 36: Autoradiograph of the Southern Blot. Genomic DNA of three ES cell clones (#A1-#E1-#G9) 
and wild-type (WT) were digested with XbaI or BamHI and hybridised with the probe shown in Fig. 24. 
The asterisks (*) indicate wild-type 5 kb BamHI or >12 kb XbaI fragment; the arrowheads demonstrate the 
signals of fragments arose by homologous recombination; XbaI generates a ~5 kb diagnostic fragment, 
BamHI a ~6 kb fragment. 
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Two ES cells (#A1 and #G9) from these positively identified clones were individually 
expanded and micro-injected into day 4 blastocysts of C57BL6/J embryos by our 
colleagues at the Transgenic Lab of ICRF, London. Injecting the ES cells into the 
blastocyst and transferring this embryo back into the uterus of a foster mother, namely, 
induce the differentiation of ES cells. 46 injected blastocysts (see Table 7) were 
transferred into day 3 pseudo-pregnant female mice (CBAxC57BL6/J females were 
used). Many of the embryos injected this way give rise to chimeric offspring that can be 
identified by coat colour contribution. 
 
 
4.4 Breeding of chimeras and heterozygous mice 
 
A chimeric mouse (Fig. 37) is created by mixing cells from a host embryo with ES cells. 
Coat colour markers are usually used for the detection of chimerism. These animals are 
mosaic for two cell lineages; the host embryo has a different genotype for coat colour 
than the ES-cells. The level of chimerism can easily be seen in the pattern formation of 
the coat. Mice are born naked; the coat becomes visible at 7-10 days of age. If one 
breeds the chimeric animal, some of the ES cell lineage will form functional gametes 
and be passed on to the next generation. 
Twelve chimeras (nine male, three female) were identified by coat colour contribution. 
Table 7 shows the injection record of the ES cell clone #G9. 
 
Table 7: Record including data of born and chimeric animals as well as sex and coat colour contribution. 
 
Total number: 
Injected 
46 Born / 
Injected 
65% Average % 129 coat 
colour contribution 
60% 
Total number: 
Born 
30 Chimeric / 
Born 
40% Highest % 129 coat 
colour contribution 
85% 
Number of 
chimeras 
12 Male / Female 9:3   
 
 
 
 
 
 
 
 
 
Figure 37: An example of a chimera, kindly provided by Ian 
Rosewell, ICRF. 
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High contribution male chimeras were backcrossed to C57BL6/J females. Germline 
transmission was determined by DNA typing of tail DNA. 
 
 
4.4.1  Germline transmission confirmed by genotyping of F1 offspring 
 
The first available heterozygous animals were among F1 mice (129 substrain and 
C57BL6/J) with brown coat colour. These mice are genetically uniform except for the 
targeted allele Tff2. 
Chimeric males were mated to C57BL6/J females to obtain ES-derived offspring that 
would analysed by a Southern blot of tail DNA to identify the heterozygous (Tff2+/-) 
mutants (Fig. 38). 
 
18 F1 mouse tails were digested to extract DNA for further analysis. For genotyping, 
Southern blot analysis was performed and at each case a sample of 15 µg DNA was 
used for digestion with BamHI. Germline transmission of the disrupted Tff2 allele could 
be confirmed by this analysis of tail DNA from different progeny (Fig. 38). 
The wild-type allele gave rise to a 5 kb BamHI fragment (refer to Fig. 36), and an 
additional 6 kb BamHI fragment indicated a heterozygous (Tff2+/-) genotype. In this way, 
germline transmission was clearly determined. Table 8 summarises the hybridisation 
results of all tails based on sex and allele arrangement. 
 
 
Figure 38: Mouse genotyping with Southern blot analysis. Genomic DNA was extracted from tail 
fragments of the F1 litter. After BamHI digestion, DNA was fractionated on 0.7% agarose gel, blotted onto 
membranes, and hybridised with the probe described in Fig. 24 (f: female, m: male, +/+ wild-type, +/- 
heterozygous). 
  Results 
 78
 
 
Table 8: Tff2 genotype (given in absolute numbers) regarding the sex in 18 tail biopsies. 
 
 wild-type (Tff2+/+) heterozygous (Tff2+/-) Σ 
female 6 3 9 
male 4 5 9 
Σ 10 8 18 
 
 
 
Presently, heterozygous mutant mouse will be mated inter se to generate progeny with 
all three genotypes, mutant (-/-), heterozygous mutant (+/-) and wild-type mice (+/+) 
according to Mendelian rules. The new offspring could then be again analysed by 
Southern blot of tail DNA to identify the genotype. By this procedure, we will finally 
identify the correct (-/-) mice to study the affected phenotype. 
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5. Discussion 
 
The trefoil factor family (TFF) is a family of peptides which bear the three-loop trefoil 
domain. They are a group of secreted proteins expressed by mucous-producing cells 
throughout the normal gastrointestinal (GI) tract in a site-specific manner.  
Over the past ten years, our knowledge has increased concerning the involvement of 
trefoil peptides in protection or mucosal defence and healing/repair processes in the GI 
tract. In the case of our study object TFF2, for example, the messenger RNA levels 
increases within 30 min after mucosal injury was induced by a cryoprobe on the serosal 
surface of the rat stomach (Alison et al., 1995). Recombinant TFF2 also increases cell 
migration in vitro models of cell wounding (Dignass et al., 1994; Playford et al., 1995) 
and acts as a cytoprotective agent in rats treated with indomethacin or aspirin (Cook et 
al., 1998; Playford et al., 1995). Among other things, the addition of trefoil factors to 
purified mucin preparations leads to a rapid increase in both optical density and 
viscosity and acts synergistically in cell migration assays (Sands and Podolsky, 1996). 
Thus, a key role of TFF peptides for maintaining the surface integrity of mucous 
epithelia is now widely accepted. Nevertheless, the underlying molecular mechanisms 
and the mode of TFF peptide action is still unknown. 
 
Since the first description of homologous recombination in mouse embryonic stem (ES) 
cells (Doetschman et al., 1988; Thomas and Capecchi, 1987), gene targeting has 
become a routine technique in mouse molecular and developmental genetics. 
Essentially, it allows not only the introduction of inactivating mutations into a gene of 
interest in ES cells, but also the passage of the targeted allele through the germline, 
enabling the assessment of gene function from the phenotypic consequences. 
 
By studying these animals, researchers can be able to determine responses to special 
treatments on a cellular, detailed histopathological level and compare the results with 
wild-type animals or other available Tff knock out mice (Lefebvre et al., 1996; Mashimo 
et al., 1996). The example of the Tff1 knockout mouse demonstrates that the results of 
in vivo studies are not always predictable or consistent with the results from in vitro 
analysis. 
 
The aim of the project was the construction of the targeting vector containing the 
mutated trefoil gene Tff2 (pL2-∆m2) and the characterisation of the germline 
transmission of the disrupted Tff2 allele in heterozygous progeny, since the final goal 
was to understand the function of the Tff2 gene. 
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This construct was transfected first into embryonic stem (ES) cell line derived from 
129/Ola, but it did not result in any positive clone. Upon using ES cells derived from 
129/Sv, one clone that by homologous recombination contained a disrupted Tff2 was 
identified. Subsequently, the successfully targeted ES cell line was injected into 
blastocysts and transplanted back to the pseudo-pregnant female mice for the breeding 
program of so-called knock-out mice. 
 
Some general principles concerning the construction of the Tff2 gene targeting vector 
and the underlying strategy must be considered and are discussed in the following 
segments. 
 
 
5.1 Replacement constructs substitute the endogenous target gene with 
the disrupted sequences 
 
When considering the anatomy of targeting constructs, two distinct vector designs can 
be used: replacement and insertion vectors.  
The insertion construct requires only a single crossover (the so-called “O-type” 
recombination), producing a duplication in the genome of the regions of homology 
present in the vector. This vector is linearised by cleavage of a unique enzyme within 
the region of homology. This type of construct is less frequently used for simple knock 
outs, in part because there is no deletion of any part of the gene; the result is in tandem 
duplication and disruption of the normal gene structure, not of the exons. In addition, a 
duplication of exon sequence without a frame-shift mutation does not exclude protein 
function, and if the insertion is targeted near the 5’ end of the gene, it is possible that it 
will regenerate a fully or partially functional promoter. To ensure that the exon 
duplication will create a mutation, it may be necessary to introduce stop codons into a 
single exon within the targeting vector. 
 
For the purpose of homologous recombination, we decided to use the replacement 
construct, which leads to a double cross over event with a linearisation site outside of 
the homologous sequences of the vector. Because no duplication of sequences 
occurred, we can be sure that Tff2 was not regenerated, and thus, can serve as an 
important feature for subsequent operations. 
However, an insertion vector can target at a 5-to 20-fold higher frequency than 
replacement vectors when supplied with the same homologous sequences (Hasty et al., 
1991c). Nevertheless, several methods exist that enhance the frequency of homologous 
recombination or lower the non-targeted events, namely, positive-negative selection 
(refer to 5.3), promoterless resistance markers (expressed only if integrated properly 
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downstream of a promoter active in ES cell; Charron et al., 1990), and markers bare of 
a polyadenylation signal produce stable transcripts only if inserted upstream of a 
genomic polyadenylation signal (Joyner et al., 1989). 
 
 
5.2 Use of increased size of homology and isogenic DNA improve the 
probability of correct targeting 
 
Without a doubt, the size of recombining region and its homology have a profound effect 
on the frequency of targeting. A total of 5-10 kb is a size proven successful in many 
targeting experiments. The targeting vector we used for homologous recombination 
contains homology sequences with a total size of 5.4 kb, which is close to the lower 
limit. 
In addition, the rate of homologous recombination grows with increasing length of the 
homologous DNA sequence (Deng and Capecchi, 1992). For example, increasing the 
total homology in a Hprt construct from 1.7 to 6.8 kb was found to result in at least a 20-
fold increase in targeted events (Hasty et al., 1991c). Although a greater length of 
homology is always desirable, it may become unwieldy when generating larger 
constructs through conventional restriction enzyme cloning methods. Another important 
result is the distribution of the sequences around the selectable marker. Reducing the 
shorter arm to a level below 1 kb results not only in diminished frequency, but also in 
reduced fidelity of recombination (Hasty et al., 1991c; Thomas et al., 1992). 
Our shorter homology arm has a size of 2.4 kb, which would be sufficient. The longer 
the stretches of homology, however, the less sensitive a PCR screening procedure can 
be in identifying recombination events. 
 
Moreover, sequence identity within the homology arms must be maintained. To avoid 
sequence differences between mouse strains, the DNA from the targeting construct 
should be isogenic with the target ES cell (this is not absolutely required, but increases 
the probability of success). It has been shown, that a single DNA mismatch is sufficient 
to dramatically decrease the rate of correct targeting. For example, homologous 
recombination at the retinoblastoma susceptibility gene (Rb) in embryonic stem cells 
derived from mouse strain 129 was 20-fold more efficient with a 129-derived targeting 
construct than with a BALB/c- derived construct (Te Riele et al., 1992). In another study, 
however, non-isogenic DNA was found to perform equivalently and only minor 
differences could be demonstrated (Deng and Capecchi, 1992). 
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The difference between these two studies could be due to the individual genes used for 
the experiments. In a few extreme cases, the use of isogenic DNA has proven to be 
crucial (Wurst et al., 1994), but the fact that non-isogenic DNA was used for the 
generation of knock-out mice demonstrates that this is not an absolute requirement. 
 
In this procedure, the ES cells initially used were derived from 129/Ola mice in order to 
use isogenic DNA, since the short arm (ClaI-BamHI fragment) of the targeting vector 
was amplified from this 129/Ola strain. The longer arm (PstI-XhoI fragment), however, 
was subcloned from the 129/Sv mouse genomic BAC library. This non-isogenie could 
be the reason for the failure to detect homologous recombinants. In response, we 
changed to AB2.2 cells derived from 129/Sv mice just as the BAC library was derived 
from 129/Sv. The screening result revealed that of 552 stably transfected ES cell clones 
one had undergone homologous recombination. 
 
Ultimately, since the frequency of homologous recombination is exponentially 
dependent on the length of homology, this factor is certainly of greater importance than 
the use of isogenic DNA (Deng and Capecchi, 1992; Thomas and Capecchi, 1987). For 
this reason, the second vector was constructed with increased size of homology (7.4 kb; 
pL2-∆Tff2, see Fig. 25) to improve the targeting frequency. In the meantime, a 
successful integration of an ES cell clone with the shorter construct pL2-∆m2 has been 
established. 
 
 
5.3 Enrichment for homologous recombinant clones by positive-negative 
selection 
 
Nearly all targeting constructs used for homologous recombination rely on the positive 
selection of a drug resistance gene, which is also used to disrupt and mutate the target 
gene. 
Most of the cells surviving positive selection, however, have not undergone homologous 
recombination, but have only integrated the targeting construct DNA at some random 
location in the genome. In order to eliminate some of these random integration events, it 
is advantageous to employ a negative selection method (Mansour et al., 1988). To 
induce a negative selection, a gene such as the Herpes Simplex Virus-thymidine kinase 
(HSV-TK) could be added to the end of the targeting construct. If homologous 
recombination occurs, the TK will get spliced out as it is not homologous to the 
endogenous gene. 
  Discussion 
 84
If, however, a random integration event occurs the TK gene will remain. Selecting 
against the random integration events by adding gancyclovir to the medium will kill any 
cell that possesses a functional TK gene. Although in reality this positive/negative 
selection strategy is not foolproof, it allows a relatively efficient selection of rare 
homologous recombination events. 
 
First, eight 96-well plates (768 colonies) were screened and none of them underwent 
any homologous recombination. A second screening with 552 ES cell (129/Sv strain cell 
line) clones yielded one homologous recombinant ES cell clone. Altogether, 1320 
clones were investigated. 
By using this strategy, at least the number of clones with random integration events that 
survived selection could be reduced, thus, facilitating the screening for the targeted 
event. 
 
 
5.4 Tff2 gene inactivation is achieved by deleting the signal peptide 
sequence and one trefoil domain 
 
The generation of a null allele would require the disruption or deletion of critical 
sequences or functional domain(s). It is important to consider the probability that alleles 
may be produced that have residual activity or other functions. Targeting events that 
leave a part of coding sequences upstream or downstream of the insertion intact might 
have the potential to produce a truncated gene product. In addition, splicing can occur 
around an exon containing the selection cassette. Generally, null alleles are more likely 
to occur after deleting or recombining the neo gene into one of the 5’ (upstream) exons 
rather than exons that encode C-terminus of the protein, since under these conditions 
minimal portions of the normal peptide are generated. 
 
In our first strategy, a stop codon in the form of the XbaI site was inserted in exon 2, 
encoding the first functional trefoil domain, to avert this danger. The palindromic 
sequence of XbaI (TCTAGA) contains the stop codon TAG and was, therefore, placed 
in frame. 
In the successfully applied targeting vector (pL2-∆m2; Fig. 24) the exon 2, which 
encodes one of the two functional trefoil domains, and the exon 1 were deleted. The 
deletion in exon 1 did not include the first 13 nucleotides up to the XhoI site. The 
following two points were the technical features to disable gene function: (1) to 
accomplish the gene function, Tff2 needs the signal peptide sequence to be secreted, 
but this information was no longer available neither one functional trefoil domain and (2) 
in order to avoid translation of a truncated protein, a stop codon in the form of the XbaI 
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site (in frame) was inserted due to the polylinker site of the vector. Any transcription of 
this targeted gene will result in an oligopeptide (length: 7 amino acids) without function. 
It is also possible that the presence of heterologous sequences, i.e. selectable marker, 
since homologous recombination can cause a number of unanticipated effects. For 
example, the presence of the neo gene, often with its own promoter, can alter the 
expression of closely neighboured genes (Olson et al., 1996; Pham et al., 1996). This 
can be a problem in gene clusters where neighboured genes are in the same family, 
since the genes affected may have similar or identical functions. This could be one 
possible explanation, why the majority of Tff1 deficient mice had lost Tff2 expression in 
the stomach (Lefebvre et al., 1996). 
To avoid similar effects, the targeting construct pL2-∆m2 already contains loxP sites 
flanking the neo gene. In the case of subtle influence of closely neighboured genes or 
trefoil genes, respectively, then neo can be removed after being targeted by transient 
expression of the Cre recombinase (Sauer, 1993). This will leave one loxP site in the 
genomic DNA. This method leads to a more exact investigation and avoids 
unanticipated effects. 
 
 
5.5 A successful strategy: a combination of two screening procedures 
 
An appropriate screening strategy should focus on to discriminating the desired 
homologous recombination event within the high background of random integration 
events. 
 
A first screening for the rapid detection of (several hundred) candidate colonies is based 
on PCR (related to the high number of ES cell clones) which can be designed to detect 
the juxtaposition of the vector and the target locus (Joyner et al., 1989). It works with 
small amounts of DNA, is fast and permits the screening of many clones. This is 
accomplished by using one primer which anneals to the heterologous marker DNA (e.g. 
neo gene) in the vector and a second one priming from the target chromosomal 
sequences just beyond the homologous sequences used in the construct (Fig. 34). 
Thus, amplification results in a unique product if homologous recombination occurs (Kim 
and Smithies, 1988). 
The efficiency of such a PCR amplification is inversely related to the distance between 
the selected primers; for practical reasons, the product should be normally in the 0.5-2.0 
kb range. Our PCR product size, used for screening, is 2.4 kb and at the beginning, it 
was technically difficult to amplify this size. By using an extend PCR program and other 
modifications, products up to 3 kb were amplified out of minimal amounts of low quality 
genomic DNA, prepared from less than 10000 ES cells. 
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In this way, homologous recombination is further characterised for correct integration 
with Southern blot analysis, the second screening strategy. The screening (of the wild-
type and the knock-out or null allele) should produce a clear result, assuming 
appropriate restriction sites in the targeting construct are available to give a distinct 
difference in product size. Normally, a screening uses an enzyme that cuts at a defined 
site both outside the region of homology and within (or on the other side of) the 
construct, in combination with a probe outside the region of homology (external). 
It is also possible to use a probe internal to the construct to detect the diagnostic 
restriction fragment. A similar-sized restriction fragment, however, may be formed in 
extremely rare cases by random insertion. The result then remains unclear, if only this 
screening method is used. 
In this case, we used an internal probe, but decided to perform two separate digestions 
(BamHI and XbaI) to identify the structure of the targeted locus at its 5’ and 3’ ends. 
Both analyses showed the expected diagnostic restriction fragments (Fig. 36). These 
data in combination with the unique PCR result (Fig. 35), prove the discriminative power 
of the internal probe we used. 
In addition to a correct band size, it is important to see that the intensity of the 
endogenous gene product after probe hybridisation is similar to that of the targeted 
gene, as long as each represents the gene on one chromosome. This is also valid for 
screening by PCR amplification. The screening of the 129/Sv ES cell clones revealed a 
positive clone, but it also showed unequal band intensity due to contamination with 
another ES cell clone (Fig. 35; c-B1). The subcloning of this mixed colony yielded pure 
clones, such as #A1 and #G9, each displaying the desirable equal intensity of the PCR 
product (Fig. 35). 
 
After screening, the targeted ES cell clone was used to generate chimeric mice by 
injection into mouse blastocyst. 
 
The high percentage chimeras were mated to C57BL/6 mice, and germline transmission 
of the disrupted Tff2 allele was confirmed by genomic Southern blot analysis of tail DNA 
from this progeny. The wild-type allele generates a 5 kb BamHI fragment and the 
heterozygous mutant contains an additional 6 kb BamHI fragment (Fig. 38). The mating 
between heterozygous male and female will generate a progeny with all three 
genotypes: homozygous mutant, heterozygous mutant, and wild-type mice. 
 
After genotyping of homozygous mutant Tff2 mice (again Southern blot analysis of tail 
DNA) detailed studies regarding the phenotypic changes is planned. 
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5.6 Genomic structure of the mouse Tff gene cluster 
 
A few years ago two groups (Burmeister and Meyer, 1997; Chinery et al., 1996b) 
assigned Tff3 to chromosome 17 of the murine genome, a region homologous with the 
trefoil gene cluster on human chromosome 21q22.3, by fluorescence in situ 
hybridization (FISH). The other Tff genes, however, were not mapped in the mouse. 
 
In order to investigate and detect the mouse Tff genes, three bacterial and one yeast 
artificial chromosome recombinants (BACs and YAC) were isolated and used for 
detailed characterisation. 
Another reason for a detailed investigation involved the study of the mice lacking Tff1 
(Lefebvre et al., 1996). One must take into consideration that the interruption of a single 
Tff gene by knock-out experiments influences the regulation of nearby Tff genes. 
Expression of Tff2, which is normally expressed in stomach, duodenum, and pancreas, 
was not detected in the stomach samples (68%) of Tff1-/- mice (Lefebvre et al., 1996; 
Tomasetto et al., 1990). Lefebvre et al. was unable to answer, however, why disruption 
of Tff1 specifically affects Tff2 in the stomach. 
 
Human TFF genes are known to be regulated in a coordinated fashion (Gött et al., 
1996). Taupin et al. have demonstrated, that mice deficient in the intestine-specific 
peptide intestinal trefoil factor (Tff3), in which colonic restitution is lethally impaired, 
show reduced expression of the gastric trefoil genes Tff2 and Tff1, suggesting that 
trefoil peptides may individually regulate transcription of the entire family (Taupin et al., 
1999). Indeed, Otto and Patel suggested that there are differences in the coordinated 
response pathways for Tff peptides that vary with age (Otto and Patel, 1999). In 
accordance with this data, the 5’-flanking regions of the corresponding human and 
murine genes show common binding sites for developmental transcription factors such 
as HNF-3 or GATA (Beck et al., 1999; Al azzeh et al., 2000) 
 
After having established the genomic trefoil gene cluster in the mouse, we now have the 
genetic material for further experiments to explore the regulation of Tff genes, for 
example, by reporter gene assays, or chromatin immunoprecipitation (ChIP), or 
Electrophoretic Mobility Shift Assay (EMSA). 
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5.6.1 Only one BAC recombinant contains all three Tff genes 
 
PCR with primers representing all three Tff genes disclosed that the YAC contained Tff2 
and Tff3 sequences, Southern blot analysis revealed that BAC 517E16 and BAC 566K2 
were carrying complete Tff1 and Tff2 sequences and only a part of exon 1 of the Tff3 
gene, while BAC 123M10 harboured all three Tff genes (Fig. 28 and 29). Hybridisation 
signals of smaller restriction fragments (Fig. 29) and in particular HindIII and PstI 
digestion patterns, which were equal compared to BAC 123M10, suggest an insert 
boundary at an identical site within Tff3 in BAC 517E16 and BAC 566K2. 
Since the HindIII site of pBeloBAC11 (the BAC vector) was used for cloning of those 
inserts, the HindIII site in exon 1 of Tff3 must have been used. 
 
Fingerprinting and PFGE of the BACs by restriction enzymes in analogy to the study of 
the human TFF contig (Gött et al., 1996) resulted in the construction of the mouse 
contig (Fig. 30). Presence or absence of particular Tff genes within the recombinants 
allowed us to place the murine Tff cluster within a genomic fragment of approximately 
40 kb. In contrast, the three human TFF genes are clustered within 50 kb in the 
chromosomal region 21q22.3, but are assembled in an identical transcriptional 
orientation (TFF1-TFF2-TFF3)(Gött et al., 1996). 
 
 
5.6.2 Mapping of the Tff cluster to mouse chromosome 17 using FISH 
 
Tff3 was previously mapped to mouse chromosome 17 (Burmeister and Meyer, 1997; 
Chinery et al., 1996b) around 17.0 cM next to the genetic markers cystathione beta 
synthase (Cbs) and alpha A crystallin (Crya1)(Hamvas et al., 1998). 
 
Therefore, FISH analysis was performed with BAC 123M10 and signals were obtained 
at 17q (Fig. 31). While larger parts of murine chromosome 17 are paralogous to human 
chromosome 6 (ca. 18 cM) and, to lesser extend, to 2p (6 cM), 18p (2 cM), 19p (1.5 cM) 
and 16p (1 cM), the human region 21q22.3 is paralogous to a small region of mouse 
chromosome 17 at position 17.2 to 17.4 cM (Hamvas et al., 1996). The FISH data 
coincide quite well with this sequence arrangement. 
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5.6.3 Murine gene distances but not the overall TFF cluster architecture are 
different from the human counterpart 
 
In order to explore the vicinity of the trefoil genes, long distance PCR was performed 
using DNA polymerase with proofreading activity. Since outward-directed primers from 
known flanking regions or 3’-UTR were chosen, the data also disclosed the 
transcriptional orientation of all three genes. 
While a PCR amplification band of 17 kb represents a 18 kb distance between third 
exon of Tff1 and the first exon of Tff2, a PCR product of 9.5 kb indicates a intergenic 
length of 11.5 kb between Tff2 and Tff3 (Fig. 32).  
 
These distances are considerably different from the distances of the human TFF gene 
cluster (12 kb between TFF1 and TFF2, 30 kb between TFF2 and TFF3)(Gött et al., 
1996; Seib et al., 1997). As reported for the human arrangement, the three murine Tff 
genes are also organised tandemly in a head-to-tail fashion (Fig. 33). 
 
 
5.6.4 Highest homology levels of amino acid sequences are found between 
corresponding trefoil domains from mouse and man 
 
The genomic structures exhibit a similar organisation in both man and mouse. For 
example, the gene size of Tff1 is equivalent to human TFF1. Tff2 would be also similar 
to the human gene, except for the larger size of human intron 2, which contains a 25 bp 
repeat that originated during simian evolution (Kayademir et al., 1998).  
 
The clustered chromosomal location strongly suggests that these genes have been 
created by a process of gene duplication and unequal crossing over. To support this 
hypothesis, the amino acid sequences of the TFF domains encoded by the central 
exons responsible for the modular character of the corresponding genes were analysed 
(Table 6). 
 
Interestingly, the murine Tff2 domains I and II encoded by two separate exons, are 
more similar to the corresponding human TFF2 domains I and II (83.7 % and 86.1%) 
than the domains I and II within each species (41.8 % and 44.2 %). This cross-species 
homology is also evident for the domains of Tff1 (72.1 %) and Tff3 (76.7%), suggesting 
that this gene cluster was generated before the rodent-primate divergence about 100 
million years ago (Novacek, 1992). 
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Since the Tff2-I domain exhibits considerable similarity to Tff1 (60.5 %; 58.1 % in the 
human counterparts) compared to Tff2-II (46.5%; 44.2% in the human counterparts), we 
propose that the Tff2-I domain evolved by a duplication event and/or unequal crossing 
over of the Tff1 domain.  
 
A few years ago, a hypothetical evolutionary history of four 11p15.5 human mucin 
genes was presented by Desseyn et al. (Desseyn et al., 1998). Three genes of this 
cluster (MUC2, MUC5AC, and MUC5B) contain several Cys-subdomains with ten 
cysteine residues that have a highly conserved position, a feature also characteristic for 
the TFFs. After comparing of the nucleotide sequences of the Cys-subdomains from the 
MUC genes, the authors argued that the three genes may have evolved from a common 
ancestral gene by two successive duplications. In addition, they postulated that 
MUC5AC and MUC5B evolved in a concerted manner via the MUC5ACB progenitor, 
while MUC2 evolved separately (Desseyn et al., 1998). 
Based on the data in Table 6 and the conserved genomic organisation, it is possible 
that an ancestral TFF gene containing only one TFF domain was duplicated to form a 
TFF1 progenitor and an ancestral TFF2-II/TFF3 progenitor. The recent TFF2 might 
have been generated in a later step after acquiring its first domain from TFF1. 
 
Database searches done by our research group (Sommer et al., 1999) revealed that an 
ancestral TFF-like domain initially arose before amphibian evolution. This is nicely 
demonstrated by the domains’ presence in teleosts and tunicate. 
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5.7 Outlook  
 
At this stage, once several male and female Tff2+/- mice have been successfully 
identified, a final breeding step is required to obtain homozygous animals exhibiting the 
phenotypic consequences of the loss of Tff2 in all cells. Thereafter, it may be possible to 
understand the functions of Tff2 by assessing the pathophysiological impact of the 
absence of this trefoil peptide in the mouse. Special attention must be given to a 
possible role in protection, healing, and tumorigenesis of the digestive tract. 
 
Since the Tff1 and Tff3 knock-out mouse models manifested either reduced or no 
expression of the other remaining trefoil genes, Tff2 knock-out mice may also reveal 
aberrant expression of the other trefoil genes, which should help to elucidate their 
coordinated regulation. 
 
For a more detailed analysis of mice lacking Tff2, gene inactivation may be controlled 
by using the Cre/loxP recombinase system. Therefore, an accurately designed, new 
targeting construct for conditional gene inactivation must be made, by means of a 
spatially (as in cell type- or tissue-specific) knockout or a temporally (through control of 
the activity or expression of the recombinase Cre) controlled knockout. 
 
  
 
 
 
 
 
 
 
SUMMARY 
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6. Summary 
 
Trefoil peptides are a group of small secreted proteins, which play an important role in 
the protecting and healing processes of the stomach and intestine. 
 
The aim of these experiments was to create a basic foundation for understanding the 
exact function and/or the mode of action of the Tff2 gene. Since in the case of human 
trefoil peptides, no naturally occurring chance mutations leading to constitutional 
diseases had been discovered, a straight forward experimental approach for new insight 
into this trefoil peptide function is to engineer a strain of so-called knock-out mice, in 
which Tff2 is missing. For Tff1 and Tff3, respectively, knock-outs were established 
already. The information gained from these experiments included: in case of Tff1-/- the 
development of gastric adenocarcinoma and mucosa abnormalities and for Tff3-/- 
decreased healing of the intestinal mucosa. 
 
By employing a replacement strategy, one allele of Tff2 was substituted in ES cells by 
homologous recombination in order to create the Tff2 knock-out mouse. 
The primary aim of this project was to construct the targeting vector (pL2-∆m2; Fig. 24), 
whereby the mouse trefoil gene Tff2 was disrupted, and to characterise the germline 
transmission of the mutant allele in heterozygous (Tff2+/-) animals. Indeed, this goal was 
realised within the scope of this work. In the near future, the mice will be mated inter se 
to generate the mutant Tff2 (-/-) knockout mice, completing the family of already existing 
trefoil knockout mice. 
 
To obtain fundamental information about the mouse trefoil gene cluster, the genomic 
structure was determined. Three bacterial and one yeast artificial chromosome 
recombinants (BACs and YAC) were identified and used for detailed characterisation by 
PCR, restriction mapping, hybridisation, and fluorescence in situ hybridisation (FISH). In 
a similar fashion to the TFF gene cluster in humans, the mouse Tff genes cover a 
region of approximately 40 kb in the transcriptional order Tff1-Tff2-Tff3 and are localised 
on chromosome 17. Based on this conserved genomic structure, a model of how 
mammalian TFF genes may have evolved by exon duplication and/or an unequal 
crossing over was proposed. 
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Zusammenfassung 
 
Kleeblattpeptide sind kleine sezernierte Proteine, die eine wichtige Rolle bei Wund-
heilungsprozessen und dem Schutz des Verdauungstraktes spielen.  
 
Das Ziel dieser Arbeit war es, Grundlagen für das Verständnis der Funktion des Tff2 
Gens zu schaffen. Für die humanen Kleeblattproteine sind keine natürlich vor-
kommenden Mutationen, welche zu konstitutionellen Krankheiten führen könnten, 
bekannt. Daher sind die sogenannten „Knockout-Mäuse“ für die Grundlagenforschung 
von großer Bedeutung, um neue Einblicke in die Wirkungsweise der Kleeblattproteine 
zu erlangen. In dieser Arbeit sollte das natürlich vorhandene Tff2 Gen ausgeschaltet 
werden, um pathologische Situationen zu simulieren und dadurch die physiologische 
Funktion des Genproduktes aufzuklären. Für Tff1 bzw. Tff3 sind Knockout-Mäuse 
bereits etabliert. Bei der Tff1-/--Maus konnte eine vermehrte Bildung von Magen-
spezifischem Adenokarzinom beobachtet werden, wogegen die Tff3-/--Maus eine 
verminderte Wundheilung der Darmschleimhaut zeigte. 
 
Durch homologe Rekombination wurde ein Allel des Tff2 Gens in den embryonalen 
Stammzellen der Maus ersetzt. Dazu wurde ein Zielvektor (pL2-∆m2; Fig. 24) 
konstruiert, in welchem das murine Kleeblattgen Tff2 deaktiviert vorliegt. Darüberhinaus 
wurde das mutierte Allel in die Keimbahn der heterozygoten (Tff2+/-) Tiere erfolgreich 
integriert. Basierend auf diesen Charakterisierungen werden nun die heterozygoten 
(Tff2+/-) Tiere untereinander gekreuzt, um letztendlich die Tff2 (-/-) Knockout-Maus zu 
züchten. Die Erzeugung dieser Maus wird die Familie der bereits bestehenden 
Kleeblatt-Knockout-Mäuse komplettieren. 
 
Als Grundlage für diese Arbeit wurde die genomische Struktur der murinen 
Kleeblattfamilie bestimmt. Drei bakterielle und eine von der Hefe abstammende 
Rekombinante (BACs und YAC) wurden identifiziert und für die detaillierte 
Charakterisierung durch PCR, Restriktionskartierung, Hybridisierung, und Fluoreszenz 
in situ Hybridisierung (FISH) verwendet. Daraus ergab sich, dass in der Maus die drei 
Tff Gene ähnlich wie im menschlichen TFF Gen-Cluster angeordnet sind. Sie er-
strecken sich über eine Länge von ca. 40 kb in der transkriptionellen Anordnung Tff1-
Tff2-Tff3 auf Chromosom 17. Aufgrund dieser konservierten Genomstruktur wurde ein 
Evolutionsmodell, basierend auf Exon-Duplikation und ungleichem Crossing-over, für 
die TFF Gene bei Säugetieren entwickelt. 
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